DDI-DrugBank.d485.s0|0-16|Ethinyl estradiol|drug
DDI-DrugBank.d485.s0|17-17|:|O
DDI-DrugBank.d485.s0|19-27|Substrate|O
DDI-DrugBank.d485.s0|29-30|of|O
DDI-DrugBank.d485.s0|32-37|CYP3A4|O
DDI-DrugBank.d485.s0|39-39|(|O
DDI-DrugBank.d485.s0|40-44|major|O
DDI-DrugBank.d485.s0|45-45|)|O
DDI-DrugBank.d485.s0|46-46|,|O
DDI-DrugBank.d485.s0|48-52|3A5-7|O
DDI-DrugBank.d485.s0|54-54|(|O
DDI-DrugBank.d485.s0|55-59|minor|O
DDI-DrugBank.d485.s0|60-60|)|O
DDI-DrugBank.d485.s0|61-61|;|O
DDI-DrugBank.d485.s1|0-7|Inhibits|O
DDI-DrugBank.d485.s1|9-14|CYP1A2|O
DDI-DrugBank.d485.s1|16-16|(|O
DDI-DrugBank.d485.s1|17-20|weak|O
DDI-DrugBank.d485.s1|21-21|)|O
DDI-DrugBank.d485.s1|22-22|,|O
DDI-DrugBank.d485.s1|24-26|2B6|O
DDI-DrugBank.d485.s1|28-28|(|O
DDI-DrugBank.d485.s1|29-32|weak|O
DDI-DrugBank.d485.s1|33-33|)|O
DDI-DrugBank.d485.s1|34-34|,|O
DDI-DrugBank.d485.s1|36-39|2C19|O
DDI-DrugBank.d485.s1|41-41|(|O
DDI-DrugBank.d485.s1|42-45|weak|O
DDI-DrugBank.d485.s1|46-46|)|O
DDI-DrugBank.d485.s1|47-47|,|O
DDI-DrugBank.d485.s1|49-51|3A4|O
DDI-DrugBank.d485.s1|53-53|(|O
DDI-DrugBank.d485.s1|54-57|weak|O
DDI-DrugBank.d485.s1|58-58|)|O
DDI-DrugBank.d485.s1|59-59|.|O
DDI-DrugBank.d485.s2|0-12|Acetaminophen|drug
DDI-DrugBank.d485.s2|13-13|:|O
DDI-DrugBank.d485.s2|15-17|May|O
DDI-DrugBank.d485.s2|19-26|increase|O
DDI-DrugBank.d485.s2|28-33|plasma|O
DDI-DrugBank.d485.s2|35-47|concentration|O
DDI-DrugBank.d485.s2|49-50|of|O
DDI-DrugBank.d485.s2|52-70|synthetic estrogens|group
DDI-DrugBank.d485.s2|71-71|,|O
DDI-DrugBank.d485.s2|73-80|possibly|O
DDI-DrugBank.d485.s2|82-83|by|O
DDI-DrugBank.d485.s2|85-94|inhibiting|O
DDI-DrugBank.d485.s2|96-106|conjugation|O
DDI-DrugBank.d485.s2|107-107|.|O
DDI-DrugBank.d485.s3|0-10|Combination|O
DDI-DrugBank.d485.s3|12-34|hormonal contraceptives|group
DDI-DrugBank.d485.s3|36-38|may|O
DDI-DrugBank.d485.s3|40-43|also|O
DDI-DrugBank.d485.s3|45-52|decrease|O
DDI-DrugBank.d485.s3|54-56|the|O
DDI-DrugBank.d485.s3|58-63|plasma|O
DDI-DrugBank.d485.s3|65-77|concentration|O
DDI-DrugBank.d485.s3|79-80|of|O
DDI-DrugBank.d485.s3|82-94|acetaminophen|drug
DDI-DrugBank.d485.s3|95-95|.|O
DDI-DrugBank.d485.s4|0-8|Acitretin|O
DDI-DrugBank.d485.s4|9-9|:|O
DDI-DrugBank.d485.s4|11-20|Interferes|O
DDI-DrugBank.d485.s4|22-25|with|O
DDI-DrugBank.d485.s4|27-29|the|O
DDI-DrugBank.d485.s4|31-43|contraceptive|O
DDI-DrugBank.d485.s4|45-50|effect|O
DDI-DrugBank.d485.s4|52-53|of|O
DDI-DrugBank.d485.s4|55-64|microdosed|O
DDI-DrugBank.d485.s4|66-85|progestin-containing|drug
DDI-DrugBank.d485.s4|87-94|minipill|O
DDI-DrugBank.d485.s4|96-107|preparations|O
DDI-DrugBank.d485.s4|108-108|.|O
DDI-DrugBank.d485.s5|0-2|The|O
DDI-DrugBank.d485.s5|4-9|effect|O
DDI-DrugBank.d485.s5|11-12|on|O
DDI-DrugBank.d485.s5|14-18|other|O
DDI-DrugBank.d485.s5|20-33|progestational|O
DDI-DrugBank.d485.s5|35-48|contraceptives|group
DDI-DrugBank.d485.s5|50-50|(|O
DDI-DrugBank.d485.s5|51-52|eg|O
DDI-DrugBank.d485.s5|53-53|,|O
DDI-DrugBank.d485.s5|55-62|implants|O
DDI-DrugBank.d485.s5|63-63|,|O
DDI-DrugBank.d485.s5|65-75|injectables|O
DDI-DrugBank.d485.s5|76-76|)|O
DDI-DrugBank.d485.s5|78-79|is|O
DDI-DrugBank.d485.s5|81-87|unknown|O
DDI-DrugBank.d485.s5|88-88|.|O
DDI-DrugBank.d485.s6|0-16|Aminoglutethimide|O
DDI-DrugBank.d485.s6|17-17|:|O
DDI-DrugBank.d485.s6|19-21|May|O
DDI-DrugBank.d485.s6|23-30|increase|O
DDI-DrugBank.d485.s6|32-34|CYP|O
DDI-DrugBank.d485.s6|36-45|metabolism|O
DDI-DrugBank.d485.s6|47-48|of|O
DDI-DrugBank.d485.s6|50-59|progestins|O
DDI-DrugBank.d485.s6|61-67|leading|O
DDI-DrugBank.d485.s6|69-70|to|O
DDI-DrugBank.d485.s6|72-79|possible|O
DDI-DrugBank.d485.s6|81-88|decrease|O
DDI-DrugBank.d485.s6|90-91|in|O
DDI-DrugBank.d485.s6|93-105|contraceptive|O
DDI-DrugBank.d485.s6|107-119|effectiveness|O
DDI-DrugBank.d485.s6|120-120|.|O
DDI-DrugBank.d485.s7|0-2|Use|O
DDI-DrugBank.d485.s7|4-5|of|O
DDI-DrugBank.d485.s7|7-7|a|O
DDI-DrugBank.d485.s7|9-41|nonhormonal contraceptive product|group
DDI-DrugBank.d485.s7|43-44|is|O
DDI-DrugBank.d485.s7|46-56|recommended|O
DDI-DrugBank.d485.s7|57-57|.|O
DDI-DrugBank.d485.s8|0-10|Antibiotics|group
DDI-DrugBank.d485.s8|12-12|(|O
DDI-DrugBank.d485.s8|13-22|ampicillin|drug
DDI-DrugBank.d485.s8|23-23|,|O
DDI-DrugBank.d485.s8|25-36|tetracycline|drug
DDI-DrugBank.d485.s8|37-37|)|O
DDI-DrugBank.d485.s8|38-38|:|O
DDI-DrugBank.d485.s8|40-48|Pregnancy|O
DDI-DrugBank.d485.s8|50-52|has|O
DDI-DrugBank.d485.s8|54-57|been|O
DDI-DrugBank.d485.s8|59-66|reported|O
DDI-DrugBank.d485.s8|68-76|following|O
DDI-DrugBank.d485.s8|78-88|concomitant|O
DDI-DrugBank.d485.s8|90-92|use|O
DDI-DrugBank.d485.s8|93-93|,|O
DDI-DrugBank.d485.s8|95-101|however|O
DDI-DrugBank.d485.s8|102-102|,|O
DDI-DrugBank.d485.s8|104-118|pharmacokinetic|O
DDI-DrugBank.d485.s8|120-126|studies|O
DDI-DrugBank.d485.s8|128-131|have|O
DDI-DrugBank.d485.s8|133-135|not|O
DDI-DrugBank.d485.s8|137-141|shown|O
DDI-DrugBank.d485.s8|143-152|consistent|O
DDI-DrugBank.d485.s8|154-160|effects|O
DDI-DrugBank.d485.s8|162-165|with|O
DDI-DrugBank.d485.s8|167-171|these|O
DDI-DrugBank.d485.s8|173-183|antibiotics|group
DDI-DrugBank.d485.s8|185-186|on|O
DDI-DrugBank.d485.s8|188-193|plasma|O
DDI-DrugBank.d485.s8|195-208|concentrations|O
DDI-DrugBank.d485.s8|210-211|of|O
DDI-DrugBank.d485.s8|213-230|synthetic steroids|group
DDI-DrugBank.d485.s8|231-231|.|O
DDI-DrugBank.d485.s9|0-2|Use|O
DDI-DrugBank.d485.s9|4-5|of|O
DDI-DrugBank.d485.s9|7-7|a|O
DDI-DrugBank.d485.s9|9-41|nonhormonal contraceptive product|group
DDI-DrugBank.d485.s9|43-44|is|O
DDI-DrugBank.d485.s9|46-56|recommended|O
DDI-DrugBank.d485.s9|57-57|.|O
DDI-DrugBank.d485.s10|0-13|Anticoagulants|group
DDI-DrugBank.d485.s10|14-14|:|O
DDI-DrugBank.d485.s10|16-26|Combination|O
DDI-DrugBank.d485.s10|28-50|hormonal contraceptives|group
DDI-DrugBank.d485.s10|52-54|may|O
DDI-DrugBank.d485.s10|56-63|increase|O
DDI-DrugBank.d485.s10|65-66|or|O
DDI-DrugBank.d485.s10|68-75|decrease|O
DDI-DrugBank.d485.s10|77-79|the|O
DDI-DrugBank.d485.s10|81-87|effects|O
DDI-DrugBank.d485.s10|89-90|of|O
DDI-DrugBank.d485.s10|92-111|coumarin derivatives|group
DDI-DrugBank.d485.s10|112-112|.|O
DDI-DrugBank.d485.s11|0-10|Combination|O
DDI-DrugBank.d485.s11|12-34|hormonal contraceptives|group
DDI-DrugBank.d485.s11|36-38|may|O
DDI-DrugBank.d485.s11|40-43|also|O
DDI-DrugBank.d485.s11|45-52|increase|O
DDI-DrugBank.d485.s11|54-57|risk|O
DDI-DrugBank.d485.s11|59-60|of|O
DDI-DrugBank.d485.s11|62-75|thromboembolic|O
DDI-DrugBank.d485.s11|77-85|disorders|O
DDI-DrugBank.d485.s11|86-86|.|O
DDI-DrugBank.d485.s12|0-14|Anticonvulsants|group
DDI-DrugBank.d485.s12|16-16|(|O
DDI-DrugBank.d485.s12|17-29|carbamazepine|drug
DDI-DrugBank.d485.s12|30-30|,|O
DDI-DrugBank.d485.s12|32-40|felbamate|drug
DDI-DrugBank.d485.s12|41-41|,|O
DDI-DrugBank.d485.s12|43-55|phenobarbital|drug
DDI-DrugBank.d485.s12|56-56|,|O
DDI-DrugBank.d485.s12|58-66|phenytoin|drug
DDI-DrugBank.d485.s12|67-67|,|O
DDI-DrugBank.d485.s12|69-78|topiramate|drug
DDI-DrugBank.d485.s12|79-79|)|O
DDI-DrugBank.d485.s12|80-80|:|O
DDI-DrugBank.d485.s12|82-89|Increase|O
DDI-DrugBank.d485.s12|91-93|the|O
DDI-DrugBank.d485.s12|95-104|metabolism|O
DDI-DrugBank.d485.s12|106-107|of|O
DDI-DrugBank.d485.s12|109-125|ethinyl estradiol|drug
DDI-DrugBank.d485.s12|127-132|and/or|O
DDI-DrugBank.d485.s12|134-137|some|O
DDI-DrugBank.d485.s12|139-148|progestins|O
DDI-DrugBank.d485.s12|149-149|,|O
DDI-DrugBank.d485.s12|151-157|leading|O
DDI-DrugBank.d485.s12|159-160|to|O
DDI-DrugBank.d485.s12|162-169|possible|O
DDI-DrugBank.d485.s12|171-178|decrease|O
DDI-DrugBank.d485.s12|180-181|in|O
DDI-DrugBank.d485.s12|183-195|contraceptive|O
DDI-DrugBank.d485.s12|197-209|effectiveness|O
DDI-DrugBank.d485.s12|210-210|.|O
DDI-DrugBank.d485.s13|0-2|Use|O
DDI-DrugBank.d485.s13|4-5|of|O
DDI-DrugBank.d485.s13|7-7|a|O
DDI-DrugBank.d485.s13|9-41|nonhormonal contraceptive product|group
DDI-DrugBank.d485.s13|43-44|is|O
DDI-DrugBank.d485.s13|46-56|recommended|O
DDI-DrugBank.d485.s13|57-57|.|O
DDI-DrugBank.d485.s14|0-12|Ascorbic acid|drug
DDI-DrugBank.d485.s14|13-13|:|O
DDI-DrugBank.d485.s14|15-19|Doses|O
DDI-DrugBank.d485.s14|21-22|of|O
DDI-DrugBank.d485.s14|24-36|ascorbic acid|drug
DDI-DrugBank.d485.s14|38-38|(|O
DDI-DrugBank.d485.s14|39-47|vitamin C|drug
DDI-DrugBank.d485.s14|48-48|)|O
DDI-DrugBank.d485.s14|50-50|1|O
DDI-DrugBank.d485.s14|52-56|g/day|O
DDI-DrugBank.d485.s14|58-61|have|O
DDI-DrugBank.d485.s14|63-66|been|O
DDI-DrugBank.d485.s14|68-75|reported|O
DDI-DrugBank.d485.s14|77-78|to|O
DDI-DrugBank.d485.s14|80-87|increase|O
DDI-DrugBank.d485.s14|89-94|plasma|O
DDI-DrugBank.d485.s14|96-108|concentration|O
DDI-DrugBank.d485.s14|110-111|of|O
DDI-DrugBank.d485.s14|113-131|synthetic estrogens|group
DDI-DrugBank.d485.s14|133-134|by|O
DDI-DrugBank.d485.s14|136-138|~47|O
DDI-DrugBank.d485.s14|139-139|%|O
DDI-DrugBank.d485.s14|140-140|,|O
DDI-DrugBank.d485.s14|142-149|possibly|O
DDI-DrugBank.d485.s14|151-152|by|O
DDI-DrugBank.d485.s14|154-163|inhibiting|O
DDI-DrugBank.d485.s14|165-175|conjugation|O
DDI-DrugBank.d485.s14|176-176|;|O
DDI-DrugBank.d485.s15|0-7|clinical|O
DDI-DrugBank.d485.s15|9-20|implications|O
DDI-DrugBank.d485.s15|22-24|are|O
DDI-DrugBank.d485.s15|26-32|unclear|O
DDI-DrugBank.d485.s15|33-33|.|O
DDI-DrugBank.d485.s16|0-11|Atorvastatin|drug
DDI-DrugBank.d485.s16|12-12|:|O
DDI-DrugBank.d485.s16|14-25|Atorvastatin|drug
DDI-DrugBank.d485.s16|27-35|increases|O
DDI-DrugBank.d485.s16|37-39|the|O
DDI-DrugBank.d485.s16|41-43|AUC|O
DDI-DrugBank.d485.s16|45-47|for|O
DDI-DrugBank.d485.s16|49-61|norethindrone|drug
DDI-DrugBank.d485.s16|63-65|and|O
DDI-DrugBank.d485.s16|67-83|ethinyl estradiol|drug
DDI-DrugBank.d485.s16|84-84|.|O
DDI-DrugBank.d485.s17|0-14|Benzodiazepines|group
DDI-DrugBank.d485.s17|15-15|:|O
DDI-DrugBank.d485.s17|17-27|Combination|O
DDI-DrugBank.d485.s17|29-51|hormonal contraceptives|group
DDI-DrugBank.d485.s17|53-55|may|O
DDI-DrugBank.d485.s17|57-64|decrease|O
DDI-DrugBank.d485.s17|66-68|the|O
DDI-DrugBank.d485.s17|70-78|clearance|O
DDI-DrugBank.d485.s17|80-81|of|O
DDI-DrugBank.d485.s17|83-86|some|O
DDI-DrugBank.d485.s17|88-102|benzodiazepines|group
DDI-DrugBank.d485.s17|104-104|(|O
DDI-DrugBank.d485.s17|105-114|alprazolam|drug
DDI-DrugBank.d485.s17|115-115|,|O
DDI-DrugBank.d485.s17|117-132|chlordiazepoxide|drug
DDI-DrugBank.d485.s17|133-133|,|O
DDI-DrugBank.d485.s17|135-142|diazepam|drug
DDI-DrugBank.d485.s17|143-143|)|O
DDI-DrugBank.d485.s17|145-147|and|O
DDI-DrugBank.d485.s17|149-156|increase|O
DDI-DrugBank.d485.s17|158-160|the|O
DDI-DrugBank.d485.s17|162-170|clearance|O
DDI-DrugBank.d485.s17|172-173|of|O
DDI-DrugBank.d485.s17|175-180|others|O
DDI-DrugBank.d485.s17|182-182|(|O
DDI-DrugBank.d485.s17|183-191|lorazepam|drug
DDI-DrugBank.d485.s17|192-192|,|O
DDI-DrugBank.d485.s17|194-201|oxazepam|drug
DDI-DrugBank.d485.s17|202-202|,|O
DDI-DrugBank.d485.s17|204-212|temazepam|drug
DDI-DrugBank.d485.s17|213-213|)|O
DDI-DrugBank.d485.s17|214-214|.|O
DDI-DrugBank.d485.s18|0-13|Clofibric acid|drug
DDI-DrugBank.d485.s18|14-14|:|O
DDI-DrugBank.d485.s18|16-26|Combination|O
DDI-DrugBank.d485.s18|28-50|hormonal contraceptives|group
DDI-DrugBank.d485.s18|52-54|may|O
DDI-DrugBank.d485.s18|56-63|increase|O
DDI-DrugBank.d485.s18|65-67|the|O
DDI-DrugBank.d485.s18|69-77|clearance|O
DDI-DrugBank.d485.s18|79-80|of|O
DDI-DrugBank.d485.s18|82-95|clofibric acid|drug
DDI-DrugBank.d485.s18|96-96|.|O
DDI-DrugBank.d485.s19|0-11|Cyclosporine|drug
DDI-DrugBank.d485.s19|12-12|:|O
DDI-DrugBank.d485.s19|14-24|Combination|O
DDI-DrugBank.d485.s19|26-48|hormonal contraceptives|group
DDI-DrugBank.d485.s19|50-52|may|O
DDI-DrugBank.d485.s19|54-60|inhibit|O
DDI-DrugBank.d485.s19|62-64|the|O
DDI-DrugBank.d485.s19|66-75|metabolism|O
DDI-DrugBank.d485.s19|77-78|of|O
DDI-DrugBank.d485.s19|80-91|cyclosporine|drug
DDI-DrugBank.d485.s19|92-92|,|O
DDI-DrugBank.d485.s19|94-100|leading|O
DDI-DrugBank.d485.s19|102-103|to|O
DDI-DrugBank.d485.s19|105-113|increased|O
DDI-DrugBank.d485.s19|115-120|plasma|O
DDI-DrugBank.d485.s19|122-135|concentrations|O
DDI-DrugBank.d485.s19|136-136|;|O
DDI-DrugBank.d485.s20|0-6|monitor|O
DDI-DrugBank.d485.s20|8-19|cyclosporine|drug
DDI-DrugBank.d485.s20|21-26|levels|O
DDI-DrugBank.d485.s20|27-27|.|O
DDI-DrugBank.d485.s21|0-5|CYP3A4|O
DDI-DrugBank.d485.s21|7-14|inducers|O
DDI-DrugBank.d485.s21|15-15|:|O
DDI-DrugBank.d485.s21|17-22|CYP3A4|O
DDI-DrugBank.d485.s21|24-31|inducers|O
DDI-DrugBank.d485.s21|33-35|may|O
DDI-DrugBank.d485.s21|37-44|decrease|O
DDI-DrugBank.d485.s21|46-48|the|O
DDI-DrugBank.d485.s21|50-63|levels/effects|O
DDI-DrugBank.d485.s21|65-66|of|O
DDI-DrugBank.d485.s21|68-84|ethinyl estradiol|drug
DDI-DrugBank.d485.s21|85-85|.|O
DDI-DrugBank.d485.s22|0-6|Example|O
DDI-DrugBank.d485.s22|8-15|inducers|O
DDI-DrugBank.d485.s22|17-23|include|O
DDI-DrugBank.d485.s22|25-41|aminoglutethimide|O
DDI-DrugBank.d485.s22|42-42|,|O
DDI-DrugBank.d485.s22|44-56|carbamazepine|drug
DDI-DrugBank.d485.s22|57-57|,|O
DDI-DrugBank.d485.s22|59-67|nafcillin|drug
DDI-DrugBank.d485.s22|68-68|,|O
DDI-DrugBank.d485.s22|70-79|nevirapine|drug
DDI-DrugBank.d485.s22|80-80|,|O
DDI-DrugBank.d485.s22|82-94|phenobarbital|drug
DDI-DrugBank.d485.s22|95-95|,|O
DDI-DrugBank.d485.s22|97-105|phenytoin|drug
DDI-DrugBank.d485.s22|106-106|,|O
DDI-DrugBank.d485.s22|108-110|and|O
DDI-DrugBank.d485.s22|112-121|rifamycins|O
DDI-DrugBank.d485.s22|122-122|.|O
DDI-DrugBank.d485.s23|0-11|Griseofulvin|drug
DDI-DrugBank.d485.s23|12-12|:|O
DDI-DrugBank.d485.s23|14-25|Griseofulvin|drug
DDI-DrugBank.d485.s23|27-29|may|O
DDI-DrugBank.d485.s23|31-36|induce|O
DDI-DrugBank.d485.s23|38-40|the|O
DDI-DrugBank.d485.s23|42-51|metabolism|O
DDI-DrugBank.d485.s23|53-54|of|O
DDI-DrugBank.d485.s23|56-66|combination|O
DDI-DrugBank.d485.s23|68-90|hormonal contraceptives|group
DDI-DrugBank.d485.s23|92-98|causing|O
DDI-DrugBank.d485.s23|100-108|menstrual|O
DDI-DrugBank.d485.s23|110-116|changes|O
DDI-DrugBank.d485.s23|117-117|;|O
DDI-DrugBank.d485.s24|0-10|pregnancies|O
DDI-DrugBank.d485.s24|12-15|have|O
DDI-DrugBank.d485.s24|17-20|been|O
DDI-DrugBank.d485.s24|22-29|reported|O
DDI-DrugBank.d485.s24|30-30|.|O
DDI-DrugBank.d485.s25|0-2|Use|O
DDI-DrugBank.d485.s25|4-5|of|O
DDI-DrugBank.d485.s25|7-13|barrier|O
DDI-DrugBank.d485.s25|15-18|form|O
DDI-DrugBank.d485.s25|20-21|of|O
DDI-DrugBank.d485.s25|23-35|contraception|O
DDI-DrugBank.d485.s25|37-38|is|O
DDI-DrugBank.d485.s25|40-48|suggested|O
DDI-DrugBank.d485.s25|50-54|while|O
DDI-DrugBank.d485.s25|56-57|on|O
DDI-DrugBank.d485.s25|59-70|griseofulvin|drug
DDI-DrugBank.d485.s25|72-78|therapy|O
DDI-DrugBank.d485.s25|79-79|.|O
DDI-DrugBank.d485.s26|0-7|Morphine|drug
DDI-DrugBank.d485.s26|8-8|:|O
DDI-DrugBank.d485.s26|10-20|Combination|O
DDI-DrugBank.d485.s26|22-44|hormonal contraceptives|group
DDI-DrugBank.d485.s26|46-48|may|O
DDI-DrugBank.d485.s26|50-57|increase|O
DDI-DrugBank.d485.s26|59-61|the|O
DDI-DrugBank.d485.s26|63-71|clearance|O
DDI-DrugBank.d485.s26|73-74|of|O
DDI-DrugBank.d485.s26|76-83|morphine|drug
DDI-DrugBank.d485.s26|84-84|.|O
DDI-DrugBank.d485.s27|0-46|Non-nucleoside reverse transcriptase inhibitors|group
DDI-DrugBank.d485.s27|48-48|(|O
DDI-DrugBank.d485.s27|49-54|NNRTIs|O
DDI-DrugBank.d485.s27|55-55|)|O
DDI-DrugBank.d485.s27|56-56|:|O
DDI-DrugBank.d485.s27|58-67|Nevirapine|drug
DDI-DrugBank.d485.s27|69-71|may|O
DDI-DrugBank.d485.s27|73-80|decrease|O
DDI-DrugBank.d485.s27|82-87|plasma|O
DDI-DrugBank.d485.s27|89-94|levels|O
DDI-DrugBank.d485.s27|96-97|of|O
DDI-DrugBank.d485.s27|99-109|combination|O
DDI-DrugBank.d485.s27|111-133|hormonal contraceptives|group
DDI-DrugBank.d485.s27|134-134|;|O
DDI-DrugBank.d485.s28|0-2|use|O
DDI-DrugBank.d485.s28|4-5|of|O
DDI-DrugBank.d485.s28|7-7|a|O
DDI-DrugBank.d485.s28|9-41|nonhormonal contraceptive product|group
DDI-DrugBank.d485.s28|43-44|is|O
DDI-DrugBank.d485.s28|46-56|recommended|O
DDI-DrugBank.d485.s28|57-57|.|O
DDI-DrugBank.d485.s29|0-1|No|O
DDI-DrugBank.d485.s29|3-6|data|O
DDI-DrugBank.d485.s29|8-10|for|O
DDI-DrugBank.d485.s29|12-22|delavirdine|drug
DDI-DrugBank.d485.s29|23-23|;|O
DDI-DrugBank.d485.s30|0-9|incomplete|O
DDI-DrugBank.d485.s30|11-14|data|O
DDI-DrugBank.d485.s30|16-18|for|O
DDI-DrugBank.d485.s30|20-28|efavirenz|drug
DDI-DrugBank.d485.s30|29-29|.|O
DDI-DrugBank.d485.s31|0-11|Prednisolone|drug
DDI-DrugBank.d485.s31|12-12|:|O
DDI-DrugBank.d485.s31|14-30|Ethinyl estradiol|drug
DDI-DrugBank.d485.s31|32-34|may|O
DDI-DrugBank.d485.s31|36-42|inhibit|O
DDI-DrugBank.d485.s31|44-46|the|O
DDI-DrugBank.d485.s31|48-57|metabolism|O
DDI-DrugBank.d485.s31|59-60|of|O
DDI-DrugBank.d485.s31|62-73|prednisolone|drug
DDI-DrugBank.d485.s31|74-74|,|O
DDI-DrugBank.d485.s31|76-82|leading|O
DDI-DrugBank.d485.s31|84-85|to|O
DDI-DrugBank.d485.s31|87-95|increased|O
DDI-DrugBank.d485.s31|97-102|plasma|O
DDI-DrugBank.d485.s31|104-117|concentrations|O
DDI-DrugBank.d485.s31|118-118|.|O
DDI-DrugBank.d485.s32|0-18|Protease inhibitors|group
DDI-DrugBank.d485.s32|19-19|:|O
DDI-DrugBank.d485.s32|21-30|Amprenavir|drug
DDI-DrugBank.d485.s32|31-31|,|O
DDI-DrugBank.d485.s32|33-41|lopinavir|drug
DDI-DrugBank.d485.s32|42-42|,|O
DDI-DrugBank.d485.s32|44-53|nelfinavir|drug
DDI-DrugBank.d485.s32|54-54|,|O
DDI-DrugBank.d485.s32|56-58|and|O
DDI-DrugBank.d485.s32|60-68|ritonavir|drug
DDI-DrugBank.d485.s32|70-73|have|O
DDI-DrugBank.d485.s32|75-78|been|O
DDI-DrugBank.d485.s32|80-84|shown|O
DDI-DrugBank.d485.s32|86-87|to|O
DDI-DrugBank.d485.s32|89-96|decrease|O
DDI-DrugBank.d485.s32|98-103|plasma|O
DDI-DrugBank.d485.s32|105-110|levels|O
DDI-DrugBank.d485.s32|112-113|of|O
DDI-DrugBank.d485.s32|115-125|combination|O
DDI-DrugBank.d485.s32|127-149|hormonal contraceptives|group
DDI-DrugBank.d485.s32|150-150|;|O
DDI-DrugBank.d485.s33|0-2|use|O
DDI-DrugBank.d485.s33|4-5|of|O
DDI-DrugBank.d485.s33|7-7|a|O
DDI-DrugBank.d485.s33|9-41|nonhormonal contraceptive product|group
DDI-DrugBank.d485.s33|43-44|is|O
DDI-DrugBank.d485.s33|46-56|recommended|O
DDI-DrugBank.d485.s33|57-57|.|O
DDI-DrugBank.d485.s34|0-8|Indinavir|drug
DDI-DrugBank.d485.s34|10-12|has|O
DDI-DrugBank.d485.s34|14-17|been|O
DDI-DrugBank.d485.s34|19-23|shown|O
DDI-DrugBank.d485.s34|25-26|to|O
DDI-DrugBank.d485.s34|28-35|increase|O
DDI-DrugBank.d485.s34|37-42|plasma|O
DDI-DrugBank.d485.s34|44-49|levels|O
DDI-DrugBank.d485.s34|51-52|of|O
DDI-DrugBank.d485.s34|54-64|combination|O
DDI-DrugBank.d485.s34|66-88|hormonal contraceptives|group
DDI-DrugBank.d485.s34|89-89|.|O
DDI-DrugBank.d485.s35|0-1|No|O
DDI-DrugBank.d485.s35|3-6|data|O
DDI-DrugBank.d485.s35|8-10|for|O
DDI-DrugBank.d485.s35|12-21|saquinavir|drug
DDI-DrugBank.d485.s35|22-22|.|O
DDI-DrugBank.d485.s36|0-7|Rifampin|drug
DDI-DrugBank.d485.s36|8-8|:|O
DDI-DrugBank.d485.s36|10-17|Rifampin|drug
DDI-DrugBank.d485.s36|19-27|increases|O
DDI-DrugBank.d485.s36|29-31|the|O
DDI-DrugBank.d485.s36|33-42|metabolism|O
DDI-DrugBank.d485.s36|44-45|of|O
DDI-DrugBank.d485.s36|47-63|ethinyl estradiol|drug
DDI-DrugBank.d485.s36|65-67|and|O
DDI-DrugBank.d485.s36|69-72|some|O
DDI-DrugBank.d485.s36|74-83|progestins|O
DDI-DrugBank.d485.s36|85-85|(|O
DDI-DrugBank.d485.s36|86-98|norethindrone|drug
DDI-DrugBank.d485.s36|99-99|)|O
DDI-DrugBank.d485.s36|101-109|resulting|O
DDI-DrugBank.d485.s36|111-112|in|O
DDI-DrugBank.d485.s36|114-122|decreased|O
DDI-DrugBank.d485.s36|124-136|contraceptive|O
DDI-DrugBank.d485.s36|138-150|effectiveness|O
DDI-DrugBank.d485.s36|152-154|and|O
DDI-DrugBank.d485.s36|156-164|increased|O
DDI-DrugBank.d485.s36|166-174|menstrual|O
DDI-DrugBank.d485.s36|176-189|irregularities|O
DDI-DrugBank.d485.s36|190-190|.|O
DDI-DrugBank.d485.s37|0-2|Use|O
DDI-DrugBank.d485.s37|4-5|of|O
DDI-DrugBank.d485.s37|7-7|a|O
DDI-DrugBank.d485.s37|9-41|nonhormonal contraceptive product|group
DDI-DrugBank.d485.s37|43-44|is|O
DDI-DrugBank.d485.s37|46-56|recommended|O
DDI-DrugBank.d485.s37|57-57|.|O
DDI-DrugBank.d485.s38|0-13|Salicylic acid|drug
DDI-DrugBank.d485.s38|14-14|:|O
DDI-DrugBank.d485.s38|16-26|Combination|O
DDI-DrugBank.d485.s38|28-50|hormonal contraceptives|group
DDI-DrugBank.d485.s38|52-54|may|O
DDI-DrugBank.d485.s38|56-63|increase|O
DDI-DrugBank.d485.s38|65-67|the|O
DDI-DrugBank.d485.s38|69-77|clearance|O
DDI-DrugBank.d485.s38|79-80|of|O
DDI-DrugBank.d485.s38|82-95|salicylic acid|drug
DDI-DrugBank.d485.s38|96-96|.|O
DDI-DrugBank.d485.s39|0-9|Selegiline|drug
DDI-DrugBank.d485.s39|10-10|:|O
DDI-DrugBank.d485.s39|12-22|Combination|O
DDI-DrugBank.d485.s39|24-46|hormonal contraceptives|group
DDI-DrugBank.d485.s39|48-50|may|O
DDI-DrugBank.d485.s39|52-59|increase|O
DDI-DrugBank.d485.s39|61-63|the|O
DDI-DrugBank.d485.s39|65-69|serum|O
DDI-DrugBank.d485.s39|71-83|concentration|O
DDI-DrugBank.d485.s39|85-86|of|O
DDI-DrugBank.d485.s39|88-97|selegiline|drug
DDI-DrugBank.d485.s39|98-98|.|O
DDI-DrugBank.d485.s40|0-11|Theophylline|drug
DDI-DrugBank.d485.s40|12-12|:|O
DDI-DrugBank.d485.s40|14-30|Ethinyl estradiol|drug
DDI-DrugBank.d485.s40|32-34|may|O
DDI-DrugBank.d485.s40|36-42|inhibit|O
DDI-DrugBank.d485.s40|44-46|the|O
DDI-DrugBank.d485.s40|48-57|metabolism|O
DDI-DrugBank.d485.s40|59-60|of|O
DDI-DrugBank.d485.s40|62-73|theophylline|drug
DDI-DrugBank.d485.s40|74-74|,|O
DDI-DrugBank.d485.s40|76-82|leading|O
DDI-DrugBank.d485.s40|84-85|to|O
DDI-DrugBank.d485.s40|87-95|increased|O
DDI-DrugBank.d485.s40|97-102|plasma|O
DDI-DrugBank.d485.s40|104-117|concentrations|O
DDI-DrugBank.d485.s40|118-118|.|O
DDI-DrugBank.d485.s41|0-24|Tricyclic antidepressants|group
DDI-DrugBank.d485.s41|26-26|(|O
DDI-DrugBank.d485.s41|27-39|amitriptyline|drug
DDI-DrugBank.d485.s41|40-40|,|O
DDI-DrugBank.d485.s41|42-51|imipramine|drug
DDI-DrugBank.d485.s41|52-52|,|O
DDI-DrugBank.d485.s41|54-66|nortriptyline|drug
DDI-DrugBank.d485.s41|67-67|)|O
DDI-DrugBank.d485.s41|68-68|:|O
DDI-DrugBank.d485.s41|70-79|Metabolism|O
DDI-DrugBank.d485.s41|81-83|may|O
DDI-DrugBank.d485.s41|85-86|be|O
DDI-DrugBank.d485.s41|88-96|inhibited|O
DDI-DrugBank.d485.s41|98-99|by|O
DDI-DrugBank.d485.s41|101-111|combination|O
DDI-DrugBank.d485.s41|113-135|hormonal contraceptives|group
DDI-DrugBank.d485.s41|136-136|,|O
DDI-DrugBank.d485.s41|138-147|increasing|O
DDI-DrugBank.d485.s41|149-154|plasma|O
DDI-DrugBank.d485.s41|156-161|levels|O
DDI-DrugBank.d485.s41|163-164|of|O
DDI-DrugBank.d485.s41|166-179|antidepressant|drug
DDI-DrugBank.d485.s41|180-180|;|O
DDI-DrugBank.d485.s42|0-2|use|O
DDI-DrugBank.d485.s42|4-10|caution|O
DDI-DrugBank.d485.s42|11-11|.|O
DDI-DrugBank.d485.s43|0-6|ETHANOL|O
DDI-DrugBank.d485.s43|8-8|/|O
DDI-DrugBank.d485.s43|10-18|NUTRITION|O
DDI-DrugBank.d485.s43|20-20|/|O
DDI-DrugBank.d485.s43|22-25|HERB|O
DDI-DrugBank.d485.s43|27-38|INTERACTIONS|O
DDI-DrugBank.d485.s43|39-39|:|O
DDI-DrugBank.d485.s43|41-44|Food|O
DDI-DrugBank.d485.s43|45-45|:|O
DDI-DrugBank.d485.s43|47-49|CNS|O
DDI-DrugBank.d485.s43|51-57|effects|O
DDI-DrugBank.d485.s43|59-60|of|O
DDI-DrugBank.d485.s43|62-69|caffeine|drug
DDI-DrugBank.d485.s43|71-73|may|O
DDI-DrugBank.d485.s43|75-76|be|O
DDI-DrugBank.d485.s43|78-85|enhanced|O
DDI-DrugBank.d485.s43|87-88|if|O
DDI-DrugBank.d485.s43|90-100|combination|O
DDI-DrugBank.d485.s43|102-124|hormonal contraceptives|group
DDI-DrugBank.d485.s43|126-128|are|O
DDI-DrugBank.d485.s43|130-133|used|O
DDI-DrugBank.d485.s43|135-146|concurrently|O
DDI-DrugBank.d485.s43|148-151|with|O
DDI-DrugBank.d485.s43|153-160|caffeine|drug
DDI-DrugBank.d485.s43|161-161|.|O
DDI-DrugBank.d485.s44|0-9|Grapefruit|O
DDI-DrugBank.d485.s44|11-15|juice|O
DDI-DrugBank.d485.s44|17-25|increases|O
DDI-DrugBank.d485.s44|27-43|ethinyl estradiol|drug
DDI-DrugBank.d485.s44|45-58|concentrations|O
DDI-DrugBank.d485.s44|60-62|and|O
DDI-DrugBank.d485.s44|64-68|would|O
DDI-DrugBank.d485.s44|70-71|be|O
DDI-DrugBank.d485.s44|73-80|expected|O
DDI-DrugBank.d485.s44|82-83|to|O
DDI-DrugBank.d485.s44|85-92|increase|O
DDI-DrugBank.d485.s44|94-105|progesterone|O
DDI-DrugBank.d485.s44|107-111|serum|O
DDI-DrugBank.d485.s44|113-118|levels|O
DDI-DrugBank.d485.s44|120-121|as|O
DDI-DrugBank.d485.s44|123-126|well|O
DDI-DrugBank.d485.s44|127-127|;|O
DDI-DrugBank.d485.s45|0-7|clinical|O
DDI-DrugBank.d485.s45|9-20|implications|O
DDI-DrugBank.d485.s45|22-24|are|O
DDI-DrugBank.d485.s45|26-32|unclear|O
DDI-DrugBank.d485.s45|33-33|.|O
DDI-DrugBank.d485.s46|0-17|Herb/Nutraceutical|O
DDI-DrugBank.d485.s46|18-18|:|O
DDI-DrugBank.d485.s46|20-21|St|O
DDI-DrugBank.d485.s46|23-27|Johns|O
DDI-DrugBank.d485.s46|29-32|wort|O
DDI-DrugBank.d485.s46|34-36|may|O
DDI-DrugBank.d485.s46|38-45|decrease|O
DDI-DrugBank.d485.s46|47-49|the|O
DDI-DrugBank.d485.s46|51-63|effectiveness|O
DDI-DrugBank.d485.s46|65-66|of|O
DDI-DrugBank.d485.s46|68-78|combination|O
DDI-DrugBank.d485.s46|80-102|hormonal contraceptives|group
DDI-DrugBank.d485.s46|104-105|by|O
DDI-DrugBank.d485.s46|107-114|inducing|O
DDI-DrugBank.d485.s46|116-122|hepatic|O
DDI-DrugBank.d485.s46|124-130|enzymes|O
DDI-DrugBank.d485.s46|131-131|.|O
DDI-DrugBank.d485.s47|0-4|Avoid|O
DDI-DrugBank.d485.s47|6-9|dong|O
DDI-DrugBank.d485.s47|11-14|quai|O
DDI-DrugBank.d485.s47|16-18|and|O
DDI-DrugBank.d485.s47|20-24|black|O
DDI-DrugBank.d485.s47|26-31|cohosh|O
DDI-DrugBank.d485.s47|33-33|(|O
DDI-DrugBank.d485.s47|34-37|have|O
DDI-DrugBank.d485.s47|39-46|estrogen|O
DDI-DrugBank.d485.s47|48-55|activity|O
DDI-DrugBank.d485.s47|56-56|)|O
DDI-DrugBank.d485.s47|57-57|.|O
DDI-DrugBank.d485.s48|0-4|Avoid|O
DDI-DrugBank.d485.s48|6-8|saw|O
DDI-DrugBank.d485.s48|10-17|palmetto|O
DDI-DrugBank.d485.s48|18-18|,|O
DDI-DrugBank.d485.s48|20-22|red|O
DDI-DrugBank.d485.s48|24-29|clover|O
DDI-DrugBank.d485.s48|30-30|,|O
DDI-DrugBank.d485.s48|32-38|ginseng|O
DDI-DrugBank.d485.s48|39-39|.|O
DDI-MedLine.d34.s0|0-11|Interactions|O
DDI-MedLine.d34.s0|13-14|of|O
DDI-MedLine.d34.s0|16-21|cobalt|O
DDI-MedLine.d34.s0|23-25|and|O
DDI-MedLine.d34.s0|27-30|iron|drug
DDI-MedLine.d34.s0|32-33|in|O
DDI-MedLine.d34.s0|35-44|absorption|O
DDI-MedLine.d34.s0|46-48|and|O
DDI-MedLine.d34.s0|50-58|retention|O
DDI-MedLine.d34.s0|59-59|.|O
DDI-MedLine.d34.s1|0-2|The|O
DDI-MedLine.d34.s1|4-10|effects|O
DDI-MedLine.d34.s1|12-13|of|O
DDI-MedLine.d34.s1|15-27|supplementary|O
DDI-MedLine.d34.s1|29-32|oral|O
DDI-MedLine.d34.s1|34-39|cobalt|O
DDI-MedLine.d34.s1|41-43|and|O
DDI-MedLine.d34.s1|45-48|iron|drug
DDI-MedLine.d34.s1|49-49|,|O
DDI-MedLine.d34.s1|51-52|as|O
DDI-MedLine.d34.s1|54-57|well|O
DDI-MedLine.d34.s1|59-60|as|O
DDI-MedLine.d34.s1|62-64|the|O
DDI-MedLine.d34.s1|66-76|interaction|O
DDI-MedLine.d34.s1|78-84|between|O
DDI-MedLine.d34.s1|86-89|both|O
DDI-MedLine.d34.s1|91-92|at|O
DDI-MedLine.d34.s1|94-96|the|O
DDI-MedLine.d34.s1|98-107|absorption|O
DDI-MedLine.d34.s1|109-112|site|O
DDI-MedLine.d34.s1|113-113|,|O
DDI-MedLine.d34.s1|115-119|fecal|O
DDI-MedLine.d34.s1|121-123|and|O
DDI-MedLine.d34.s1|125-131|urinary|O
DDI-MedLine.d34.s1|133-141|excretion|O
DDI-MedLine.d34.s1|143-144|as|O
DDI-MedLine.d34.s1|146-149|well|O
DDI-MedLine.d34.s1|151-152|as|O
DDI-MedLine.d34.s1|154-156|the|O
DDI-MedLine.d34.s1|158-166|retention|O
DDI-MedLine.d34.s1|168-169|of|O
DDI-MedLine.d34.s1|171-175|these|O
DDI-MedLine.d34.s1|177-181|trace|O
DDI-MedLine.d34.s1|183-190|elements|O
DDI-MedLine.d34.s1|192-195|were|O
DDI-MedLine.d34.s1|197-206|determined|O
DDI-MedLine.d34.s1|208-209|by|O
DDI-MedLine.d34.s1|211-215|using|O
DDI-MedLine.d34.s1|217-220|four|O
DDI-MedLine.d34.s1|222-226|diets|O
DDI-MedLine.d34.s1|228-237|containing|O
DDI-MedLine.d34.s1|239-244|either|O
DDI-MedLine.d34.s1|246-246|9|O
DDI-MedLine.d34.s1|248-249|or|O
DDI-MedLine.d34.s1|251-252|63|O
DDI-MedLine.d34.s1|254-266|micrograms/kg|O
DDI-MedLine.d34.s1|268-269|of|O
DDI-MedLine.d34.s1|271-272|Co|O
DDI-MedLine.d34.s1|274-276|and|O
DDI-MedLine.d34.s1|278-279|48|O
DDI-MedLine.d34.s1|281-282|or|O
DDI-MedLine.d34.s1|284-286|446|O
DDI-MedLine.d34.s1|288-292|mg/kg|O
DDI-MedLine.d34.s1|294-295|of|O
DDI-MedLine.d34.s1|297-298|Fe|O
DDI-MedLine.d34.s1|300-303|over|O
DDI-MedLine.d34.s1|305-305|a|O
DDI-MedLine.d34.s1|307-312|period|O
DDI-MedLine.d34.s1|314-315|of|O
DDI-MedLine.d34.s1|317-318|19|O
DDI-MedLine.d34.s1|320-323|days|O
DDI-MedLine.d34.s1|325-326|in|O
DDI-MedLine.d34.s1|328-328|a|O
DDI-MedLine.d34.s1|330-334|total|O
DDI-MedLine.d34.s1|336-337|of|O
DDI-MedLine.d34.s1|339-340|24|O
DDI-MedLine.d34.s1|342-345|rats|O
DDI-MedLine.d34.s1|346-346|.|O
DDI-MedLine.d34.s2|0-8|Retention|O
DDI-MedLine.d34.s2|10-12|was|O
DDI-MedLine.d34.s2|14-23|calculated|O
DDI-MedLine.d34.s2|25-26|by|O
DDI-MedLine.d34.s2|28-30|the|O
DDI-MedLine.d34.s2|32-38|balance|O
DDI-MedLine.d34.s2|40-48|technique|O
DDI-MedLine.d34.s2|50-52|and|O
DDI-MedLine.d34.s2|54-55|by|O
DDI-MedLine.d34.s2|57-59|the|O
DDI-MedLine.d34.s2|61-71|comparative|O
DDI-MedLine.d34.s2|73-81|slaughter|O
DDI-MedLine.d34.s2|83-91|technique|O
DDI-MedLine.d34.s2|92-92|.|O
DDI-MedLine.d34.s3|0-4|After|O
DDI-MedLine.d34.s3|6-8|one|O
DDI-MedLine.d34.s3|10-12|day|O
DDI-MedLine.d34.s3|13-13|,|O
DDI-MedLine.d34.s3|15-19|fecal|O
DDI-MedLine.d34.s3|21-22|as|O
DDI-MedLine.d34.s3|24-27|well|O
DDI-MedLine.d34.s3|29-30|as|O
DDI-MedLine.d34.s3|32-38|urinary|O
DDI-MedLine.d34.s3|40-48|excretion|O
DDI-MedLine.d34.s3|50-51|of|O
DDI-MedLine.d34.s3|53-56|both|O
DDI-MedLine.d34.s3|58-65|elements|O
DDI-MedLine.d34.s3|67-69|had|O
DDI-MedLine.d34.s3|71-77|already|O
DDI-MedLine.d34.s3|79-87|responded|O
DDI-MedLine.d34.s3|89-90|to|O
DDI-MedLine.d34.s3|92-94|the|O
DDI-MedLine.d34.s3|96-102|dietary|O
DDI-MedLine.d34.s3|104-113|treatments|O
DDI-MedLine.d34.s3|114-114|,|O
DDI-MedLine.d34.s3|116-119|with|O
DDI-MedLine.d34.s3|121-128|constant|O
DDI-MedLine.d34.s3|130-135|values|O
DDI-MedLine.d34.s3|137-141|being|O
DDI-MedLine.d34.s3|143-149|reached|O
DDI-MedLine.d34.s3|151-155|after|O
DDI-MedLine.d34.s3|157-169|approximately|O
DDI-MedLine.d34.s3|171-175|three|O
DDI-MedLine.d34.s3|177-180|days|O
DDI-MedLine.d34.s3|181-181|.|O
DDI-MedLine.d34.s4|0-5|Cobalt|O
DDI-MedLine.d34.s4|7-15|excretion|O
DDI-MedLine.d34.s4|17-19|was|O
DDI-MedLine.d34.s4|21-28|enhanced|O
DDI-MedLine.d34.s4|30-31|by|O
DDI-MedLine.d34.s4|33-45|supplementary|O
DDI-MedLine.d34.s4|47-52|cobalt|O
DDI-MedLine.d34.s4|53-53|;|O
DDI-MedLine.d34.s5|0-4|fecal|O
DDI-MedLine.d34.s5|6-14|excretion|O
DDI-MedLine.d34.s5|15-15|,|O
DDI-MedLine.d34.s5|17-19|too|O
DDI-MedLine.d34.s5|20-20|,|O
DDI-MedLine.d34.s5|22-24|was|O
DDI-MedLine.d34.s5|26-34|increased|O
DDI-MedLine.d34.s5|36-37|by|O
DDI-MedLine.d34.s5|39-51|supplementary|O
DDI-MedLine.d34.s5|53-56|iron|drug
DDI-MedLine.d34.s5|57-57|;|O
DDI-MedLine.d34.s6|0-6|whereas|O
DDI-MedLine.d34.s6|8-14|urinary|O
DDI-MedLine.d34.s6|16-24|excretion|O
DDI-MedLine.d34.s6|26-28|was|O
DDI-MedLine.d34.s6|30-38|decreased|O
DDI-MedLine.d34.s6|40-41|in|O
DDI-MedLine.d34.s6|43-46|both|O
DDI-MedLine.d34.s6|48-52|cases|O
DDI-MedLine.d34.s6|53-53|.|O
DDI-MedLine.d34.s7|0-9|Additional|O
DDI-MedLine.d34.s7|11-14|iron|O
DDI-MedLine.d34.s7|16-28|significantly|O
DDI-MedLine.d34.s7|30-38|inhibited|O
DDI-MedLine.d34.s7|40-42|the|O
DDI-MedLine.d34.s7|44-53|absorption|O
DDI-MedLine.d34.s7|55-56|of|O
DDI-MedLine.d34.s7|58-63|cobalt|O
DDI-MedLine.d34.s7|65-66|in|O
DDI-MedLine.d34.s7|68-71|both|O
DDI-MedLine.d34.s7|73-79|dietary|O
DDI-MedLine.d34.s7|81-86|cobalt|O
DDI-MedLine.d34.s7|88-97|treatments|O
DDI-MedLine.d34.s7|98-98|.|O
DDI-MedLine.d34.s8|0-2|The|O
DDI-MedLine.d34.s8|4-8|lower|O
DDI-MedLine.d34.s8|10-13|rate|O
DDI-MedLine.d34.s8|15-16|of|O
DDI-MedLine.d34.s8|18-27|absorption|O
DDI-MedLine.d34.s8|29-30|in|O
DDI-MedLine.d34.s8|32-34|the|O
DDI-MedLine.d34.s8|36-41|groups|O
DDI-MedLine.d34.s8|43-51|receiving|O
DDI-MedLine.d34.s8|53-55|446|O
DDI-MedLine.d34.s8|57-58|mg|O
DDI-MedLine.d34.s8|60-61|Fe|O
DDI-MedLine.d34.s8|63-69|instead|O
DDI-MedLine.d34.s8|71-72|of|O
DDI-MedLine.d34.s8|74-75|48|O
DDI-MedLine.d34.s8|77-78|mg|O
DDI-MedLine.d34.s8|80-81|of|O
DDI-MedLine.d34.s8|83-84|Fe|O
DDI-MedLine.d34.s8|86-88|per|O
DDI-MedLine.d34.s8|90-91|kg|O
DDI-MedLine.d34.s8|93-96|diet|O
DDI-MedLine.d34.s8|98-105|resulted|O
DDI-MedLine.d34.s8|107-108|in|O
DDI-MedLine.d34.s8|110-110|a|O
DDI-MedLine.d34.s8|112-120|decreased|O
DDI-MedLine.d34.s8|122-126|renal|O
DDI-MedLine.d34.s8|128-136|excretion|O
DDI-MedLine.d34.s8|138-139|of|O
DDI-MedLine.d34.s8|141-146|cobalt|O
DDI-MedLine.d34.s8|147-147|.|O
DDI-MedLine.d34.s9|0-11|Consequently|O
DDI-MedLine.d34.s9|12-12|,|O
DDI-MedLine.d34.s9|14-16|the|O
DDI-MedLine.d34.s9|18-23|effect|O
DDI-MedLine.d34.s9|25-26|of|O
DDI-MedLine.d34.s9|28-31|iron|drug
DDI-MedLine.d34.s9|33-34|on|O
DDI-MedLine.d34.s9|36-38|the|O
DDI-MedLine.d34.s9|40-48|retention|O
DDI-MedLine.d34.s9|50-51|of|O
DDI-MedLine.d34.s9|53-58|cobalt|O
DDI-MedLine.d34.s9|60-62|was|O
DDI-MedLine.d34.s9|64-68|lower|O
DDI-MedLine.d34.s9|70-73|than|O
DDI-MedLine.d34.s9|75-76|on|O
DDI-MedLine.d34.s9|78-87|absorption|O
DDI-MedLine.d34.s9|88-88|.|O
DDI-MedLine.d34.s10|0-3|This|O
DDI-MedLine.d34.s10|5-12|suggests|O
DDI-MedLine.d34.s10|14-17|that|O
DDI-MedLine.d34.s10|19-30|interactions|O
DDI-MedLine.d34.s10|32-38|between|O
DDI-MedLine.d34.s10|40-42|the|O
DDI-MedLine.d34.s10|44-46|two|O
DDI-MedLine.d34.s10|48-55|elements|O
DDI-MedLine.d34.s10|57-60|only|O
DDI-MedLine.d34.s10|62-65|take|O
DDI-MedLine.d34.s10|67-71|place|O
DDI-MedLine.d34.s10|73-74|at|O
DDI-MedLine.d34.s10|76-78|the|O
DDI-MedLine.d34.s10|80-83|site|O
DDI-MedLine.d34.s10|85-86|of|O
DDI-MedLine.d34.s10|88-97|absorption|O
DDI-MedLine.d34.s10|98-98|.|O
DDI-MedLine.d34.s11|0-6|Because|O
DDI-MedLine.d34.s11|8-9|of|O
DDI-MedLine.d34.s11|11-13|the|O
DDI-MedLine.d34.s11|15-17|low|O
DDI-MedLine.d34.s11|19-25|dietary|O
DDI-MedLine.d34.s11|27-32|cobalt|O
DDI-MedLine.d34.s11|34-46|concentration|O
DDI-MedLine.d34.s11|48-49|as|O
DDI-MedLine.d34.s11|51-58|compared|O
DDI-MedLine.d34.s11|60-61|to|O
DDI-MedLine.d34.s11|63-65|the|O
DDI-MedLine.d34.s11|67-70|iron|O
DDI-MedLine.d34.s11|72-79|contents|O
DDI-MedLine.d34.s11|81-82|of|O
DDI-MedLine.d34.s11|84-86|the|O
DDI-MedLine.d34.s11|88-92|diets|O
DDI-MedLine.d34.s11|93-93|,|O
DDI-MedLine.d34.s11|95-96|no|O
DDI-MedLine.d34.s11|98-103|effect|O
DDI-MedLine.d34.s11|105-106|of|O
DDI-MedLine.d34.s11|108-113|cobalt|O
DDI-MedLine.d34.s11|115-116|on|O
DDI-MedLine.d34.s11|118-121|iron|drug
DDI-MedLine.d34.s11|123-132|absorption|O
DDI-MedLine.d34.s11|134-136|and|O
DDI-MedLine.d34.s11|138-146|excretion|O
DDI-MedLine.d34.s11|148-155|occurred|O
DDI-MedLine.d34.s11|156-156|.|O
DDI-MedLine.d34.s12|0-10|Differences|O
DDI-MedLine.d34.s12|12-13|in|O
DDI-MedLine.d34.s12|15-18|iron|O
DDI-MedLine.d34.s12|20-26|balance|O
DDI-MedLine.d34.s12|28-31|were|O
DDI-MedLine.d34.s12|33-36|only|O
DDI-MedLine.d34.s12|38-45|observed|O
DDI-MedLine.d34.s12|47-53|between|O
DDI-MedLine.d34.s12|55-58|both|O
DDI-MedLine.d34.s12|60-66|dietary|O
DDI-MedLine.d34.s12|68-81|concentrations|O
DDI-MedLine.d34.s12|82-82|,|O
DDI-MedLine.d34.s12|84-90|showing|O
DDI-MedLine.d34.s12|92-92|a|O
DDI-MedLine.d34.s12|94-99|higher|O
DDI-MedLine.d34.s12|101-108|absolute|O
DDI-MedLine.d34.s12|110-112|but|O
DDI-MedLine.d34.s12|114-114|a|O
DDI-MedLine.d34.s12|116-120|lower|O
DDI-MedLine.d34.s12|122-129|relative|O
DDI-MedLine.d34.s12|131-140|absorption|O
DDI-MedLine.d34.s12|142-143|as|O
DDI-MedLine.d34.s12|145-148|well|O
DDI-MedLine.d34.s12|150-151|as|O
DDI-MedLine.d34.s12|153-161|retention|O
DDI-MedLine.d34.s12|163-164|in|O
DDI-MedLine.d34.s12|166-168|the|O
DDI-MedLine.d34.s12|170-175|groups|O
DDI-MedLine.d34.s12|177-179|fed|O
DDI-MedLine.d34.s12|181-187|further|O
DDI-MedLine.d34.s12|189-191|Fe.|O
DDI-MedLine.d34.s12|192-192|(|O
DDI-MedLine.d34.s12|193-200|ABSTRACT|O
DDI-MedLine.d34.s12|202-210|TRUNCATED|O
DDI-MedLine.d34.s12|212-213|AT|O
DDI-MedLine.d34.s12|215-217|250|O
DDI-MedLine.d34.s12|219-223|WORDS|O
DDI-MedLine.d34.s12|224-224|)|O
DDI-DrugBank.d665.s0|0-9|Concurrent|O
DDI-DrugBank.d665.s0|11-24|administration|O
DDI-DrugBank.d665.s0|26-27|of|O
DDI-DrugBank.d665.s0|29-54|bacteriostatic antibiotics|group
DDI-DrugBank.d665.s0|56-56|(|O
DDI-DrugBank.d665.s0|57-60|e.g.|O
DDI-DrugBank.d665.s0|61-61|,|O
DDI-DrugBank.d665.s0|63-74|erythromycin|drug
DDI-DrugBank.d665.s0|75-75|,|O
DDI-DrugBank.d665.s0|77-88|tetracycline|drug
DDI-DrugBank.d665.s0|89-89|)|O
DDI-DrugBank.d665.s0|91-93|may|O
DDI-DrugBank.d665.s0|95-102|diminish|O
DDI-DrugBank.d665.s0|104-106|the|O
DDI-DrugBank.d665.s0|108-119|bactericidal|O
DDI-DrugBank.d665.s0|121-127|effects|O
DDI-DrugBank.d665.s0|129-130|of|O
DDI-DrugBank.d665.s0|132-142|penicillins|group
DDI-DrugBank.d665.s0|144-145|by|O
DDI-DrugBank.d665.s0|147-153|slowing|O
DDI-DrugBank.d665.s0|155-157|the|O
DDI-DrugBank.d665.s0|159-162|rate|O
DDI-DrugBank.d665.s0|164-165|of|O
DDI-DrugBank.d665.s0|167-175|bacterial|O
DDI-DrugBank.d665.s0|177-182|growth|O
DDI-DrugBank.d665.s0|183-183|.|O
DDI-DrugBank.d665.s1|0-11|Bactericidal|O
DDI-DrugBank.d665.s1|13-18|agents|O
DDI-DrugBank.d665.s1|20-23|work|O
DDI-DrugBank.d665.s1|25-28|most|O
DDI-DrugBank.d665.s1|30-40|effectively|O
DDI-DrugBank.d665.s1|42-48|against|O
DDI-DrugBank.d665.s1|50-52|the|O
DDI-DrugBank.d665.s1|54-61|immature|O
DDI-DrugBank.d665.s1|63-66|cell|O
DDI-DrugBank.d665.s1|68-71|wall|O
DDI-DrugBank.d665.s1|73-74|of|O
DDI-DrugBank.d665.s1|76-82|rapidly|O
DDI-DrugBank.d665.s1|84-96|proliferating|O
DDI-DrugBank.d665.s1|98-111|microorganisms|O
DDI-DrugBank.d665.s1|112-112|.|O
DDI-DrugBank.d665.s2|0-3|This|O
DDI-DrugBank.d665.s2|5-7|has|O
DDI-DrugBank.d665.s2|9-12|been|O
DDI-DrugBank.d665.s2|14-25|demonstrated|O
DDI-DrugBank.d665.s2|27-28|in|O
DDI-DrugBank.d665.s2|30-34|vitro|O
DDI-DrugBank.d665.s2|35-35|;|O
DDI-DrugBank.d665.s3|0-6|however|O
DDI-DrugBank.d665.s3|7-7|,|O
DDI-DrugBank.d665.s3|9-11|the|O
DDI-DrugBank.d665.s3|13-20|clinical|O
DDI-DrugBank.d665.s3|22-33|significance|O
DDI-DrugBank.d665.s3|35-36|of|O
DDI-DrugBank.d665.s3|38-41|this|O
DDI-DrugBank.d665.s3|43-53|interaction|O
DDI-DrugBank.d665.s3|55-56|is|O
DDI-DrugBank.d665.s3|58-60|not|O
DDI-DrugBank.d665.s3|62-65|well|O
DDI-DrugBank.d665.s3|67-76|documented|O
DDI-DrugBank.d665.s3|77-77|.|O
DDI-DrugBank.d665.s4|0-4|There|O
DDI-DrugBank.d665.s4|6-8|are|O
DDI-DrugBank.d665.s4|10-12|few|O
DDI-DrugBank.d665.s4|14-21|clinical|O
DDI-DrugBank.d665.s4|23-32|situations|O
DDI-DrugBank.d665.s4|34-35|in|O
DDI-DrugBank.d665.s4|37-41|which|O
DDI-DrugBank.d665.s4|43-45|the|O
DDI-DrugBank.d665.s4|47-56|concurrent|O
DDI-DrugBank.d665.s4|58-60|use|O
DDI-DrugBank.d665.s4|62-63|of|O
DDI-DrugBank.d665.s4|65-66|''|O
DDI-DrugBank.d665.s4|67-72|static|O
DDI-DrugBank.d665.s4|73-74|''|O
DDI-DrugBank.d665.s4|76-78|and|O
DDI-DrugBank.d665.s4|80-81|''|O
DDI-DrugBank.d665.s4|82-86|cidal|O
DDI-DrugBank.d665.s4|88-89|''|O
DDI-DrugBank.d665.s4|91-101|antibiotics|group
DDI-DrugBank.d665.s4|103-105|are|O
DDI-DrugBank.d665.s4|107-115|indicated|O
DDI-DrugBank.d665.s4|116-116|.|O
DDI-DrugBank.d665.s5|0-6|However|O
DDI-DrugBank.d665.s5|7-7|,|O
DDI-DrugBank.d665.s5|9-10|in|O
DDI-DrugBank.d665.s5|12-19|selected|O
DDI-DrugBank.d665.s5|21-33|circumstances|O
DDI-DrugBank.d665.s5|35-36|in|O
DDI-DrugBank.d665.s5|38-42|which|O
DDI-DrugBank.d665.s5|44-47|such|O
DDI-DrugBank.d665.s5|49-55|therapy|O
DDI-DrugBank.d665.s5|57-58|is|O
DDI-DrugBank.d665.s5|60-70|appropriate|O
DDI-DrugBank.d665.s5|71-71|,|O
DDI-DrugBank.d665.s5|73-77|using|O
DDI-DrugBank.d665.s5|79-86|adequate|O
DDI-DrugBank.d665.s5|88-92|doses|O
DDI-DrugBank.d665.s5|94-95|of|O
DDI-DrugBank.d665.s5|97-116|antibacterial agents|group
DDI-DrugBank.d665.s5|118-120|and|O
DDI-DrugBank.d665.s5|122-130|beginning|O
DDI-DrugBank.d665.s5|132-141|penicillin|drug
DDI-DrugBank.d665.s5|143-149|therapy|O
DDI-DrugBank.d665.s5|151-155|first|O
DDI-DrugBank.d665.s5|156-156|,|O
DDI-DrugBank.d665.s5|158-163|should|O
DDI-DrugBank.d665.s5|165-172|minimize|O
DDI-DrugBank.d665.s5|174-176|the|O
DDI-DrugBank.d665.s5|178-186|potential|O
DDI-DrugBank.d665.s5|188-190|for|O
DDI-DrugBank.d665.s5|192-202|interaction|O
DDI-DrugBank.d665.s5|203-203|.|O
DDI-DrugBank.d665.s6|0-9|Penicillin|drug
DDI-DrugBank.d665.s6|11-15|blood|O
DDI-DrugBank.d665.s6|17-22|levels|O
DDI-DrugBank.d665.s6|24-26|may|O
DDI-DrugBank.d665.s6|28-29|be|O
DDI-DrugBank.d665.s6|31-39|prolonged|O
DDI-DrugBank.d665.s6|41-42|by|O
DDI-DrugBank.d665.s6|44-53|concurrent|O
DDI-DrugBank.d665.s6|55-68|administration|O
DDI-DrugBank.d665.s6|70-71|of|O
DDI-DrugBank.d665.s6|73-82|probenecid|drug
DDI-DrugBank.d665.s6|84-88|which|O
DDI-DrugBank.d665.s6|90-95|blocks|O
DDI-DrugBank.d665.s6|97-99|the|O
DDI-DrugBank.d665.s6|101-105|renal|O
DDI-DrugBank.d665.s6|107-113|tubular|O
DDI-DrugBank.d665.s6|115-123|secretion|O
DDI-DrugBank.d665.s6|125-126|of|O
DDI-DrugBank.d665.s6|128-138|penicillins|O
DDI-DrugBank.d665.s6|139-139|.|O
DDI-DrugBank.d665.s7|0-11|Displacement|O
DDI-DrugBank.d665.s7|13-14|of|O
DDI-DrugBank.d665.s7|16-25|penicillin|drug
DDI-DrugBank.d665.s7|27-30|from|O
DDI-DrugBank.d665.s7|32-37|plasma|O
DDI-DrugBank.d665.s7|39-45|protein|O
DDI-DrugBank.d665.s7|47-53|binding|O
DDI-DrugBank.d665.s7|55-59|sites|O
DDI-DrugBank.d665.s7|61-64|will|O
DDI-DrugBank.d665.s7|66-72|elevate|O
DDI-DrugBank.d665.s7|74-76|the|O
DDI-DrugBank.d665.s7|78-82|level|O
DDI-DrugBank.d665.s7|84-85|of|O
DDI-DrugBank.d665.s7|87-90|free|O
DDI-DrugBank.d665.s7|92-101|penicillin|drug
DDI-DrugBank.d665.s7|103-104|in|O
DDI-DrugBank.d665.s7|106-108|the|O
DDI-DrugBank.d665.s7|110-114|serum|O
DDI-DrugBank.d665.s7|115-115|.|O
DDI-DrugBank.d585.s0|0-2|The|O
DDI-DrugBank.d585.s0|4-12|following|O
DDI-DrugBank.d585.s0|14-19|agents|O
DDI-DrugBank.d585.s0|21-23|may|O
DDI-DrugBank.d585.s0|25-32|increase|O
DDI-DrugBank.d585.s0|34-40|certain|O
DDI-DrugBank.d585.s0|42-48|actions|O
DDI-DrugBank.d585.s0|50-51|or|O
DDI-DrugBank.d585.s0|53-56|side|O
DDI-DrugBank.d585.s0|58-64|effects|O
DDI-DrugBank.d585.s0|66-67|of|O
DDI-DrugBank.d585.s0|69-89|anticholinergic drugs|group
DDI-DrugBank.d585.s0|90-90|:|O
DDI-DrugBank.d585.s0|92-101|amantadine|drug
DDI-DrugBank.d585.s0|102-102|,|O
DDI-DrugBank.d585.s0|104-124|antiarrhythmic agents|group
DDI-DrugBank.d585.s0|126-127|of|O
DDI-DrugBank.d585.s0|129-133|class|O
DDI-DrugBank.d585.s0|135-135|I|O
DDI-DrugBank.d585.s0|137-137|(|O
DDI-DrugBank.d585.s0|138-141|e.g.|O
DDI-DrugBank.d585.s0|142-142|,|O
DDI-DrugBank.d585.s0|144-152|quinidine|drug
DDI-DrugBank.d585.s0|153-153|)|O
DDI-DrugBank.d585.s0|154-154|,|O
DDI-DrugBank.d585.s0|156-169|antihistamines|group
DDI-DrugBank.d585.s0|170-170|,|O
DDI-DrugBank.d585.s0|172-191|antipsychotic agents|group
DDI-DrugBank.d585.s0|193-193|(|O
DDI-DrugBank.d585.s0|194-197|e.g.|O
DDI-DrugBank.d585.s0|198-198|,|O
DDI-DrugBank.d585.s0|200-213|phenothiazines|group
DDI-DrugBank.d585.s0|214-214|)|O
DDI-DrugBank.d585.s0|215-215|,|O
DDI-DrugBank.d585.s0|217-231|benzodiazepines|group
DDI-DrugBank.d585.s0|232-232|,|O
DDI-DrugBank.d585.s0|234-247|MAO inhibitors|group
DDI-DrugBank.d585.s0|248-248|,|O
DDI-DrugBank.d585.s0|250-268|narcotic analgesics|group
DDI-DrugBank.d585.s0|270-270|(|O
DDI-DrugBank.d585.s0|271-274|e.g.|O
DDI-DrugBank.d585.s0|275-275|,|O
DDI-DrugBank.d585.s0|277-286|meperidine|drug
DDI-DrugBank.d585.s0|287-287|)|O
DDI-DrugBank.d585.s0|288-288|,|O
DDI-DrugBank.d585.s0|290-297|nitrates|group
DDI-DrugBank.d585.s0|299-301|and|O
DDI-DrugBank.d585.s0|303-310|nitrites|O
DDI-DrugBank.d585.s0|311-311|,|O
DDI-DrugBank.d585.s0|313-334|sympathomimetic agents|group
DDI-DrugBank.d585.s0|335-335|,|O
DDI-DrugBank.d585.s0|337-361|tricyclic antidepressants|group
DDI-DrugBank.d585.s0|362-362|,|O
DDI-DrugBank.d585.s0|364-366|and|O
DDI-DrugBank.d585.s0|368-372|other|O
DDI-DrugBank.d585.s0|374-378|drugs|O
DDI-DrugBank.d585.s0|380-385|having|O
DDI-DrugBank.d585.s0|387-401|anticholinergic|O
DDI-DrugBank.d585.s0|403-410|activity|O
DDI-DrugBank.d585.s0|411-411|.|O
DDI-DrugBank.d585.s1|0-15|Anticholinergics|group
DDI-DrugBank.d585.s1|17-26|antagonize|O
DDI-DrugBank.d585.s1|28-30|the|O
DDI-DrugBank.d585.s1|32-38|effects|O
DDI-DrugBank.d585.s1|40-41|of|O
DDI-DrugBank.d585.s1|43-61|antiglaucoma agents|group
DDI-DrugBank.d585.s1|62-62|.|O
DDI-DrugBank.d585.s2|0-20|Anticholinergic drugs|group
DDI-DrugBank.d585.s2|22-23|in|O
DDI-DrugBank.d585.s2|25-27|the|O
DDI-DrugBank.d585.s2|29-36|presence|O
DDI-DrugBank.d585.s2|38-39|of|O
DDI-DrugBank.d585.s2|41-49|increased|O
DDI-DrugBank.d585.s2|51-61|intraocular|O
DDI-DrugBank.d585.s2|63-70|pressure|O
DDI-DrugBank.d585.s2|72-74|may|O
DDI-DrugBank.d585.s2|76-77|be|O
DDI-DrugBank.d585.s2|79-87|hazardous|O
DDI-DrugBank.d585.s2|89-92|when|O
DDI-DrugBank.d585.s2|94-98|taken|O
DDI-DrugBank.d585.s2|100-111|concurrently|O
DDI-DrugBank.d585.s2|113-116|with|O
DDI-DrugBank.d585.s2|118-123|agents|O
DDI-DrugBank.d585.s2|125-128|such|O
DDI-DrugBank.d585.s2|130-131|as|O
DDI-DrugBank.d585.s2|133-147|corticosteroids|group
DDI-DrugBank.d585.s2|148-148|.|O
DDI-DrugBank.d585.s3|0-21|Anticholinergic agents|group
DDI-DrugBank.d585.s3|23-25|may|O
DDI-DrugBank.d585.s3|27-32|affect|O
DDI-DrugBank.d585.s3|34-49|gastrointestinal|O
DDI-DrugBank.d585.s3|51-60|absorption|O
DDI-DrugBank.d585.s3|62-63|of|O
DDI-DrugBank.d585.s3|65-71|various|O
DDI-DrugBank.d585.s3|73-77|drugs|O
DDI-DrugBank.d585.s3|78-78|,|O
DDI-DrugBank.d585.s3|80-83|such|O
DDI-DrugBank.d585.s3|85-86|as|O
DDI-DrugBank.d585.s3|88-93|slowly|O
DDI-DrugBank.d585.s3|95-104|dissolving|O
DDI-DrugBank.d585.s3|106-111|dosage|O
DDI-DrugBank.d585.s3|113-117|forms|O
DDI-DrugBank.d585.s3|119-120|of|O
DDI-DrugBank.d585.s3|122-128|digoxin|drug
DDI-DrugBank.d585.s3|129-129|;|O
DDI-DrugBank.d585.s4|0-8|increased|O
DDI-DrugBank.d585.s4|10-14|serum|O
DDI-DrugBank.d585.s4|16-22|digoxin|drug
DDI-DrugBank.d585.s4|24-37|concentrations|O
DDI-DrugBank.d585.s4|39-41|may|O
DDI-DrugBank.d585.s4|43-48|result|O
DDI-DrugBank.d585.s4|49-49|.|O
DDI-DrugBank.d585.s5|0-20|Anticholinergic drugs|group
DDI-DrugBank.d585.s5|22-24|may|O
DDI-DrugBank.d585.s5|26-35|antagonize|O
DDI-DrugBank.d585.s5|37-39|the|O
DDI-DrugBank.d585.s5|41-47|effects|O
DDI-DrugBank.d585.s5|49-50|of|O
DDI-DrugBank.d585.s5|52-56|drugs|O
DDI-DrugBank.d585.s5|58-61|that|O
DDI-DrugBank.d585.s5|63-67|alter|O
DDI-DrugBank.d585.s5|69-84|gastrointestinal|O
DDI-DrugBank.d585.s5|86-93|motility|O
DDI-DrugBank.d585.s5|94-94|,|O
DDI-DrugBank.d585.s5|96-99|such|O
DDI-DrugBank.d585.s5|101-102|as|O
DDI-DrugBank.d585.s5|104-117|metoclopramide|drug
DDI-DrugBank.d585.s5|118-118|.|O
DDI-DrugBank.d585.s6|0-6|Because|O
DDI-DrugBank.d585.s6|8-15|antacids|group
DDI-DrugBank.d585.s6|17-19|may|O
DDI-DrugBank.d585.s6|21-29|interfere|O
DDI-DrugBank.d585.s6|31-34|with|O
DDI-DrugBank.d585.s6|36-38|the|O
DDI-DrugBank.d585.s6|40-49|absorption|O
DDI-DrugBank.d585.s6|51-52|of|O
DDI-DrugBank.d585.s6|54-75|anticholinergic agents|group
DDI-DrugBank.d585.s6|76-76|,|O
DDI-DrugBank.d585.s6|78-89|simultaneous|O
DDI-DrugBank.d585.s6|91-93|use|O
DDI-DrugBank.d585.s6|95-96|of|O
DDI-DrugBank.d585.s6|98-102|these|O
DDI-DrugBank.d585.s6|104-108|drugs|O
DDI-DrugBank.d585.s6|110-115|should|O
DDI-DrugBank.d585.s6|117-118|be|O
DDI-DrugBank.d585.s6|120-126|avoided|O
DDI-DrugBank.d585.s6|127-127|.|O
DDI-DrugBank.d585.s7|0-2|The|O
DDI-DrugBank.d585.s7|4-13|inhibiting|O
DDI-DrugBank.d585.s7|15-21|effects|O
DDI-DrugBank.d585.s7|23-24|of|O
DDI-DrugBank.d585.s7|26-46|anticholinergic drugs|group
DDI-DrugBank.d585.s7|48-49|on|O
DDI-DrugBank.d585.s7|51-57|gastric|O
DDI-DrugBank.d585.s7|59-70|hydrochloric|O
DDI-DrugBank.d585.s7|72-75|acid|O
DDI-DrugBank.d585.s7|77-85|secretion|O
DDI-DrugBank.d585.s7|87-89|are|O
DDI-DrugBank.d585.s7|91-101|antagonized|O
DDI-DrugBank.d585.s7|103-104|by|O
DDI-DrugBank.d585.s7|106-111|agents|O
DDI-DrugBank.d585.s7|113-116|used|O
DDI-DrugBank.d585.s7|118-119|to|O
DDI-DrugBank.d585.s7|121-125|treat|O
DDI-DrugBank.d585.s7|127-138|achlorhydria|O
DDI-DrugBank.d585.s7|140-142|and|O
DDI-DrugBank.d585.s7|144-148|those|O
DDI-DrugBank.d585.s7|150-153|used|O
DDI-DrugBank.d585.s7|155-156|to|O
DDI-DrugBank.d585.s7|158-161|test|O
DDI-DrugBank.d585.s7|163-169|gastric|O
DDI-DrugBank.d585.s7|171-179|secretion|O
DDI-DrugBank.d585.s7|180-180|.|O
DDI-DrugBank.d361.s0|0-10|Combination|O
DDI-DrugBank.d361.s0|12-18|Therapy|O
DDI-DrugBank.d361.s0|19-19|:|O
DDI-DrugBank.d361.s0|21-23|Any|O
DDI-DrugBank.d361.s0|25-28|form|O
DDI-DrugBank.d361.s0|30-31|of|O
DDI-DrugBank.d361.s0|33-39|therapy|O
DDI-DrugBank.d361.s0|41-45|which|O
DDI-DrugBank.d361.s0|47-50|adds|O
DDI-DrugBank.d361.s0|52-53|to|O
DDI-DrugBank.d361.s0|55-57|the|O
DDI-DrugBank.d361.s0|59-64|stress|O
DDI-DrugBank.d361.s0|66-67|of|O
DDI-DrugBank.d361.s0|69-71|the|O
DDI-DrugBank.d361.s0|73-79|patient|O
DDI-DrugBank.d361.s0|80-80|,|O
DDI-DrugBank.d361.s0|82-91|interferes|O
DDI-DrugBank.d361.s0|93-96|with|O
DDI-DrugBank.d361.s0|98-106|nutrition|O
DDI-DrugBank.d361.s0|108-109|or|O
DDI-DrugBank.d361.s0|111-119|depresses|O
DDI-DrugBank.d361.s0|121-124|bone|O
DDI-DrugBank.d361.s0|126-131|marrow|O
DDI-DrugBank.d361.s0|133-140|function|O
DDI-DrugBank.d361.s0|142-145|will|O
DDI-DrugBank.d361.s0|147-154|increase|O
DDI-DrugBank.d361.s0|156-158|the|O
DDI-DrugBank.d361.s0|160-167|toxicity|O
DDI-DrugBank.d361.s0|169-170|of|O
DDI-DrugBank.d361.s0|172-182|Floxuridine|drug
DDI-DrugBank.d361.s0|183-183|.|O
DDI-DrugBank.d469.s0|0-4|Drugs|O
DDI-DrugBank.d469.s0|6-10|which|O
DDI-DrugBank.d469.s0|12-14|may|O
DDI-DrugBank.d469.s0|16-22|enhance|O
DDI-DrugBank.d469.s0|24-26|the|O
DDI-DrugBank.d469.s0|28-40|neuromuscular|O
DDI-DrugBank.d469.s0|42-49|blocking|O
DDI-DrugBank.d469.s0|51-56|action|O
DDI-DrugBank.d469.s0|58-59|of|O
DDI-DrugBank.d469.s0|61-68|TRACRIUM|O
DDI-DrugBank.d469.s0|70-76|include|O
DDI-DrugBank.d469.s0|77-77|:|O
DDI-DrugBank.d469.s0|79-87|enflurane|drug
DDI-DrugBank.d469.s0|88-88|;|O
DDI-DrugBank.d469.s1|0-9|isoflurane|drug
DDI-DrugBank.d469.s1|10-10|;|O
DDI-DrugBank.d469.s2|0-8|halothane|drug
DDI-DrugBank.d469.s2|9-9|;|O
DDI-DrugBank.d469.s3|0-6|certain|O
DDI-DrugBank.d469.s3|8-18|antibiotics|group
DDI-DrugBank.d469.s3|19-19|,|O
DDI-DrugBank.d469.s3|21-30|especially|O
DDI-DrugBank.d469.s3|32-34|the|O
DDI-DrugBank.d469.s3|36-50|aminoglycosides|group
DDI-DrugBank.d469.s3|52-54|and|O
DDI-DrugBank.d469.s3|56-65|polymyxins|O
DDI-DrugBank.d469.s3|66-66|;|O
DDI-DrugBank.d469.s4|0-6|lithium|drug
DDI-DrugBank.d469.s4|7-7|;|O
DDI-DrugBank.d469.s5|0-8|magnesium|drug
DDI-DrugBank.d469.s5|10-14|salts|O
DDI-DrugBank.d469.s5|15-15|;|O
DDI-DrugBank.d469.s6|0-11|procainamide|drug
DDI-DrugBank.d469.s6|12-12|;|O
DDI-DrugBank.d469.s7|0-4|Drugs|O
DDI-DrugBank.d469.s7|6-10|which|O
DDI-DrugBank.d469.s7|12-14|may|O
DDI-DrugBank.d469.s7|16-22|enhance|O
DDI-DrugBank.d469.s7|24-26|the|O
DDI-DrugBank.d469.s7|28-40|neuromuscular|O
DDI-DrugBank.d469.s7|42-49|blocking|O
DDI-DrugBank.d469.s7|51-56|action|O
DDI-DrugBank.d469.s7|58-59|of|O
DDI-DrugBank.d469.s7|61-68|TRACRIUM|O
DDI-DrugBank.d469.s7|70-76|include|O
DDI-DrugBank.d469.s7|77-77|:|O
DDI-DrugBank.d469.s7|79-87|enflurane|drug
DDI-DrugBank.d469.s7|88-88|;|O
DDI-DrugBank.d469.s7|89-98|isoflurane|drug
DDI-DrugBank.d469.s7|99-99|;|O
DDI-DrugBank.d469.s7|100-108|halothane|drug
DDI-DrugBank.d469.s7|109-109|;|O
DDI-DrugBank.d469.s7|110-116|certain|O
DDI-DrugBank.d469.s7|118-128|antibiotics|group
DDI-DrugBank.d469.s7|129-129|,|O
DDI-DrugBank.d469.s7|131-140|especially|O
DDI-DrugBank.d469.s7|142-144|the|O
DDI-DrugBank.d469.s7|146-160|aminoglycosides|group
DDI-DrugBank.d469.s7|162-164|and|O
DDI-DrugBank.d469.s7|166-175|polymyxins|O
DDI-DrugBank.d469.s7|176-176|;|O
DDI-DrugBank.d469.s7|177-183|lithium|drug
DDI-DrugBank.d469.s7|184-184|;|O
DDI-DrugBank.d469.s7|185-193|magnesium|drug
DDI-DrugBank.d469.s7|195-199|salts|O
DDI-DrugBank.d469.s7|200-200|;|O
DDI-DrugBank.d469.s7|201-212|procainamide|drug
DDI-DrugBank.d469.s7|213-213|;|O
DDI-DrugBank.d469.s7|214-216|and|O
DDI-DrugBank.d469.s7|218-226|quinidine|drug
DDI-DrugBank.d469.s7|227-227|.|O
DDI-DrugBank.d469.s8|0-1|If|O
DDI-DrugBank.d469.s8|3-7|other|O
DDI-DrugBank.d469.s8|9-24|muscle relaxants|group
DDI-DrugBank.d469.s8|26-28|are|O
DDI-DrugBank.d469.s8|30-33|used|O
DDI-DrugBank.d469.s8|35-40|during|O
DDI-DrugBank.d469.s8|42-44|the|O
DDI-DrugBank.d469.s8|46-49|same|O
DDI-DrugBank.d469.s8|51-59|procedure|O
DDI-DrugBank.d469.s8|60-60|,|O
DDI-DrugBank.d469.s8|62-64|the|O
DDI-DrugBank.d469.s8|66-76|possibility|O
DDI-DrugBank.d469.s8|78-79|of|O
DDI-DrugBank.d469.s8|81-81|a|O
DDI-DrugBank.d469.s8|83-93|synergistic|O
DDI-DrugBank.d469.s8|95-96|or|O
DDI-DrugBank.d469.s8|98-107|antagonist|O
DDI-DrugBank.d469.s8|109-114|effect|O
DDI-DrugBank.d469.s8|116-121|should|O
DDI-DrugBank.d469.s8|123-124|be|O
DDI-DrugBank.d469.s8|126-135|considered|O
DDI-DrugBank.d469.s8|136-136|.|O
DDI-DrugBank.d469.s9|0-2|The|O
DDI-DrugBank.d469.s9|4-8|prior|O
DDI-DrugBank.d469.s9|10-23|administration|O
DDI-DrugBank.d469.s9|25-26|of|O
DDI-DrugBank.d469.s9|28-42|succinylcholine|drug
DDI-DrugBank.d469.s9|44-47|does|O
DDI-DrugBank.d469.s9|49-51|not|O
DDI-DrugBank.d469.s9|53-59|enhance|O
DDI-DrugBank.d469.s9|61-63|the|O
DDI-DrugBank.d469.s9|65-72|duration|O
DDI-DrugBank.d469.s9|73-73|,|O
DDI-DrugBank.d469.s9|75-77|but|O
DDI-DrugBank.d469.s9|79-86|quickens|O
DDI-DrugBank.d469.s9|88-90|the|O
DDI-DrugBank.d469.s9|92-96|onset|O
DDI-DrugBank.d469.s9|98-100|and|O
DDI-DrugBank.d469.s9|102-104|may|O
DDI-DrugBank.d469.s9|106-113|increase|O
DDI-DrugBank.d469.s9|115-117|the|O
DDI-DrugBank.d469.s9|119-123|depth|O
DDI-DrugBank.d469.s9|124-124|,|O
DDI-DrugBank.d469.s9|126-127|of|O
DDI-DrugBank.d469.s9|129-141|neuromuscular|O
DDI-DrugBank.d469.s9|143-147|block|O
DDI-DrugBank.d469.s9|149-155|induced|O
DDI-DrugBank.d469.s9|157-158|by|O
DDI-DrugBank.d469.s9|160-167|TRACRIUM|O
DDI-DrugBank.d469.s9|168-168|.|O
DDI-DrugBank.d469.s10|0-7|TRACRIUM|brand
DDI-DrugBank.d469.s10|9-14|should|O
DDI-DrugBank.d469.s10|16-18|not|O
DDI-DrugBank.d469.s10|20-21|be|O
DDI-DrugBank.d469.s10|23-34|administered|O
DDI-DrugBank.d469.s10|36-40|until|O
DDI-DrugBank.d469.s10|42-42|a|O
DDI-DrugBank.d469.s10|44-50|patient|O
DDI-DrugBank.d469.s10|52-54|has|O
DDI-DrugBank.d469.s10|56-64|recovered|O
DDI-DrugBank.d469.s10|66-69|from|O
DDI-DrugBank.d469.s10|71-93|succinylcholine-induced|O
DDI-DrugBank.d469.s10|95-107|neuromuscular|O
DDI-DrugBank.d469.s10|109-113|block|O
DDI-DrugBank.d469.s10|114-114|.|O
DDI-DrugBank.d499.s0|0-2|The|O
DDI-DrugBank.d499.s0|4-12|following|O
DDI-DrugBank.d499.s0|14-17|drug|O
DDI-DrugBank.d499.s0|19-30|interactions|O
DDI-DrugBank.d499.s0|32-35|were|O
DDI-DrugBank.d499.s0|37-43|studied|O
DDI-DrugBank.d499.s0|45-48|with|O
DDI-DrugBank.d499.s0|50-59|ketoprofen|O
DDI-DrugBank.d499.s0|61-65|doses|O
DDI-DrugBank.d499.s0|67-68|of|O
DDI-DrugBank.d499.s0|70-72|200|O
DDI-DrugBank.d499.s0|74-79|mg/day|O
DDI-DrugBank.d499.s0|80-80|.|O
DDI-DrugBank.d499.s1|0-2|The|O
DDI-DrugBank.d499.s1|4-14|possibility|O
DDI-DrugBank.d499.s1|16-17|of|O
DDI-DrugBank.d499.s1|19-27|increased|O
DDI-DrugBank.d499.s1|29-39|interaction|O
DDI-DrugBank.d499.s1|41-46|should|O
DDI-DrugBank.d499.s1|48-49|be|O
DDI-DrugBank.d499.s1|51-54|kept|O
DDI-DrugBank.d499.s1|56-57|in|O
DDI-DrugBank.d499.s1|59-62|mind|O
DDI-DrugBank.d499.s1|64-67|when|O
DDI-DrugBank.d499.s1|69-74|Orudis|brand
DDI-DrugBank.d499.s1|76-80|doses|O
DDI-DrugBank.d499.s1|82-88|greater|O
DDI-DrugBank.d499.s1|90-93|than|O
DDI-DrugBank.d499.s1|95-96|50|O
DDI-DrugBank.d499.s1|98-99|mg|O
DDI-DrugBank.d499.s1|101-102|as|O
DDI-DrugBank.d499.s1|104-104|a|O
DDI-DrugBank.d499.s1|106-111|single|O
DDI-DrugBank.d499.s1|113-116|dose|O
DDI-DrugBank.d499.s1|118-119|or|O
DDI-DrugBank.d499.s1|121-123|200|O
DDI-DrugBank.d499.s1|125-126|mg|O
DDI-DrugBank.d499.s1|128-129|of|O
DDI-DrugBank.d499.s1|131-140|ketoprofen|drug
DDI-DrugBank.d499.s1|142-144|per|O
DDI-DrugBank.d499.s1|146-148|day|O
DDI-DrugBank.d499.s1|150-152|are|O
DDI-DrugBank.d499.s1|154-157|used|O
DDI-DrugBank.d499.s1|159-171|concomitantly|O
DDI-DrugBank.d499.s1|173-176|with|O
DDI-DrugBank.d499.s1|178-183|highly|O
DDI-DrugBank.d499.s1|185-189|bound|O
DDI-DrugBank.d499.s1|191-195|drugs|O
DDI-DrugBank.d499.s1|196-196|.|O
DDI-DrugBank.d499.s2|0-0|1|O
DDI-DrugBank.d499.s2|1-1|.|O
DDI-DrugBank.d499.s3|0-7|Antacids|group
DDI-DrugBank.d499.s3|8-8|:|O
DDI-DrugBank.d499.s3|10-20|Concomitant|O
DDI-DrugBank.d499.s3|22-35|administration|O
DDI-DrugBank.d499.s3|37-38|of|O
DDI-DrugBank.d499.s3|40-58|magnesium hydroxide|drug
DDI-DrugBank.d499.s3|60-62|and|O
DDI-DrugBank.d499.s3|64-81|aluminum hydroxide|drug
DDI-DrugBank.d499.s3|83-86|does|O
DDI-DrugBank.d499.s3|88-90|not|O
DDI-DrugBank.d499.s3|92-100|interfere|O
DDI-DrugBank.d499.s3|102-105|with|O
DDI-DrugBank.d499.s3|107-109|the|O
DDI-DrugBank.d499.s3|111-114|rate|O
DDI-DrugBank.d499.s3|116-117|or|O
DDI-DrugBank.d499.s3|119-124|extent|O
DDI-DrugBank.d499.s3|126-127|of|O
DDI-DrugBank.d499.s3|129-131|the|O
DDI-DrugBank.d499.s3|133-142|absorption|O
DDI-DrugBank.d499.s3|144-145|of|O
DDI-DrugBank.d499.s3|147-156|ketoprofen|drug
DDI-DrugBank.d499.s3|158-169|administered|O
DDI-DrugBank.d499.s3|171-172|as|O
DDI-DrugBank.d499.s3|174-179|Orudis|O
DDI-DrugBank.d499.s3|180-180|.|O
DDI-DrugBank.d499.s4|0-0|2|O
DDI-DrugBank.d499.s4|1-1|.|O
DDI-DrugBank.d499.s5|0-6|Aspirin|brand
DDI-DrugBank.d499.s5|7-7|:|O
DDI-DrugBank.d499.s5|9-18|Ketoprofen|drug
DDI-DrugBank.d499.s5|20-23|does|O
DDI-DrugBank.d499.s5|25-27|not|O
DDI-DrugBank.d499.s5|29-33|alter|O
DDI-DrugBank.d499.s5|35-41|aspirin|brand
DDI-DrugBank.d499.s5|43-52|absorption|O
DDI-DrugBank.d499.s5|53-53|;|O
DDI-DrugBank.d499.s6|0-6|however|O
DDI-DrugBank.d499.s6|7-7|,|O
DDI-DrugBank.d499.s6|9-10|in|O
DDI-DrugBank.d499.s6|12-12|a|O
DDI-DrugBank.d499.s6|14-18|study|O
DDI-DrugBank.d499.s6|20-21|of|O
DDI-DrugBank.d499.s6|23-24|12|O
DDI-DrugBank.d499.s6|26-31|normal|O
DDI-DrugBank.d499.s6|33-40|subjects|O
DDI-DrugBank.d499.s6|41-41|,|O
DDI-DrugBank.d499.s6|43-52|concurrent|O
DDI-DrugBank.d499.s6|54-67|administration|O
DDI-DrugBank.d499.s6|69-70|of|O
DDI-DrugBank.d499.s6|72-78|aspirin|brand
DDI-DrugBank.d499.s6|80-88|decreased|O
DDI-DrugBank.d499.s6|90-99|ketoprofen|drug
DDI-DrugBank.d499.s6|101-107|protein|O
DDI-DrugBank.d499.s6|109-115|binding|O
DDI-DrugBank.d499.s6|117-119|and|O
DDI-DrugBank.d499.s6|121-129|increased|O
DDI-DrugBank.d499.s6|131-140|ketoprofen|O
DDI-DrugBank.d499.s6|142-147|plasma|O
DDI-DrugBank.d499.s6|149-157|clearance|O
DDI-DrugBank.d499.s6|159-162|from|O
DDI-DrugBank.d499.s6|164-167|0.07|O
DDI-DrugBank.d499.s6|169-174|L/kg/h|O
DDI-DrugBank.d499.s6|176-182|without|O
DDI-DrugBank.d499.s6|184-190|aspirin|brand
DDI-DrugBank.d499.s6|192-193|to|O
DDI-DrugBank.d499.s6|195-198|0.11|O
DDI-DrugBank.d499.s6|200-205|L/kg/h|O
DDI-DrugBank.d499.s6|207-210|with|O
DDI-DrugBank.d499.s6|212-218|aspirin|brand
DDI-DrugBank.d499.s6|219-219|.|O
DDI-DrugBank.d499.s7|0-2|The|O
DDI-DrugBank.d499.s7|4-11|clinical|O
DDI-DrugBank.d499.s7|13-24|significance|O
DDI-DrugBank.d499.s7|26-27|of|O
DDI-DrugBank.d499.s7|29-33|these|O
DDI-DrugBank.d499.s7|35-41|changes|O
DDI-DrugBank.d499.s7|43-45|has|O
DDI-DrugBank.d499.s7|47-49|not|O
DDI-DrugBank.d499.s7|51-54|been|O
DDI-DrugBank.d499.s7|56-65|adequately|O
DDI-DrugBank.d499.s7|67-73|studied|O
DDI-DrugBank.d499.s7|74-74|.|O
DDI-DrugBank.d499.s8|0-8|Therefore|O
DDI-DrugBank.d499.s8|9-9|,|O
DDI-DrugBank.d499.s8|11-20|concurrent|O
DDI-DrugBank.d499.s8|22-24|use|O
DDI-DrugBank.d499.s8|26-27|of|O
DDI-DrugBank.d499.s8|29-35|aspirin|brand
DDI-DrugBank.d499.s8|37-39|and|O
DDI-DrugBank.d499.s8|41-50|ketoprofen|drug
DDI-DrugBank.d499.s8|52-53|is|O
DDI-DrugBank.d499.s8|55-57|not|O
DDI-DrugBank.d499.s8|59-69|recommended|O
DDI-DrugBank.d499.s8|70-70|.|O
DDI-DrugBank.d499.s9|0-0|3|O
DDI-DrugBank.d499.s9|1-1|.|O
DDI-DrugBank.d499.s10|0-7|Diuretic|O
DDI-DrugBank.d499.s10|8-8|:|O
DDI-DrugBank.d499.s10|10-28|Hydrochlorothiazide|drug
DDI-DrugBank.d499.s10|29-29|,|O
DDI-DrugBank.d499.s10|31-35|given|O
DDI-DrugBank.d499.s10|37-49|concomitantly|O
DDI-DrugBank.d499.s10|51-54|with|O
DDI-DrugBank.d499.s10|56-65|ketoprofen|drug
DDI-DrugBank.d499.s10|66-66|,|O
DDI-DrugBank.d499.s10|68-75|produces|O
DDI-DrugBank.d499.s10|77-77|a|O
DDI-DrugBank.d499.s10|79-87|reduction|O
DDI-DrugBank.d499.s10|89-90|in|O
DDI-DrugBank.d499.s10|92-98|urinary|O
DDI-DrugBank.d499.s10|100-108|potassium|O
DDI-DrugBank.d499.s10|110-112|and|O
DDI-DrugBank.d499.s10|114-121|chloride|O
DDI-DrugBank.d499.s10|123-131|excretion|O
DDI-DrugBank.d499.s10|133-140|compared|O
DDI-DrugBank.d499.s10|142-143|to|O
DDI-DrugBank.d499.s10|145-163|hydrochlorothiazide|drug
DDI-DrugBank.d499.s10|165-169|alone|O
DDI-DrugBank.d499.s10|170-170|.|O
DDI-DrugBank.d499.s11|0-7|Patients|O
DDI-DrugBank.d499.s11|9-14|taking|O
DDI-DrugBank.d499.s11|16-24|diuretics|group
DDI-DrugBank.d499.s11|26-28|are|O
DDI-DrugBank.d499.s11|30-31|at|O
DDI-DrugBank.d499.s11|33-33|a|O
DDI-DrugBank.d499.s11|35-41|greater|O
DDI-DrugBank.d499.s11|43-46|risk|O
DDI-DrugBank.d499.s11|48-49|of|O
DDI-DrugBank.d499.s11|51-60|developing|O
DDI-DrugBank.d499.s11|62-66|renal|O
DDI-DrugBank.d499.s11|68-74|failure|O
DDI-DrugBank.d499.s11|76-84|secondary|O
DDI-DrugBank.d499.s11|86-87|to|O
DDI-DrugBank.d499.s11|89-89|a|O
DDI-DrugBank.d499.s11|91-98|decrease|O
DDI-DrugBank.d499.s11|100-101|in|O
DDI-DrugBank.d499.s11|103-107|renal|O
DDI-DrugBank.d499.s11|109-113|blood|O
DDI-DrugBank.d499.s11|115-118|flow|O
DDI-DrugBank.d499.s11|120-125|caused|O
DDI-DrugBank.d499.s11|127-128|by|O
DDI-DrugBank.d499.s11|130-142|prostaglandin|O
DDI-DrugBank.d499.s11|144-153|inhibition|O
DDI-DrugBank.d499.s11|154-154|.|O
DDI-DrugBank.d499.s12|0-0|4|O
DDI-DrugBank.d499.s12|1-1|.|O
DDI-DrugBank.d499.s13|0-6|Digoxin|drug
DDI-DrugBank.d499.s13|7-7|:|O
DDI-DrugBank.d499.s13|9-10|In|O
DDI-DrugBank.d499.s13|12-12|a|O
DDI-DrugBank.d499.s13|14-18|study|O
DDI-DrugBank.d499.s13|20-21|in|O
DDI-DrugBank.d499.s13|23-24|12|O
DDI-DrugBank.d499.s13|26-33|patients|O
DDI-DrugBank.d499.s13|35-38|with|O
DDI-DrugBank.d499.s13|40-49|congestive|O
DDI-DrugBank.d499.s13|51-55|heart|O
DDI-DrugBank.d499.s13|57-63|failure|O
DDI-DrugBank.d499.s13|65-69|where|O
DDI-DrugBank.d499.s13|71-80|ketoprofen|drug
DDI-DrugBank.d499.s13|82-84|and|O
DDI-DrugBank.d499.s13|86-92|digoxin|drug
DDI-DrugBank.d499.s13|94-97|were|O
DDI-DrugBank.d499.s13|99-111|concomitantly|O
DDI-DrugBank.d499.s13|113-124|administered|O
DDI-DrugBank.d499.s13|125-125|,|O
DDI-DrugBank.d499.s13|127-136|ketoprofen|drug
DDI-DrugBank.d499.s13|138-140|did|O
DDI-DrugBank.d499.s13|142-144|not|O
DDI-DrugBank.d499.s13|146-150|alter|O
DDI-DrugBank.d499.s13|152-154|the|O
DDI-DrugBank.d499.s13|156-160|serum|O
DDI-DrugBank.d499.s13|162-167|levels|O
DDI-DrugBank.d499.s13|169-170|of|O
DDI-DrugBank.d499.s13|172-178|digoxin|drug
DDI-DrugBank.d499.s13|179-179|.|O
DDI-DrugBank.d499.s14|0-0|5|O
DDI-DrugBank.d499.s14|1-1|.|O
DDI-DrugBank.d499.s15|0-7|Warfarin|drug
DDI-DrugBank.d499.s15|8-8|:|O
DDI-DrugBank.d499.s15|10-11|In|O
DDI-DrugBank.d499.s15|13-13|a|O
DDI-DrugBank.d499.s15|15-24|short-term|O
DDI-DrugBank.d499.s15|26-35|controlled|O
DDI-DrugBank.d499.s15|37-41|study|O
DDI-DrugBank.d499.s15|43-44|in|O
DDI-DrugBank.d499.s15|46-47|14|O
DDI-DrugBank.d499.s15|49-54|normal|O
DDI-DrugBank.d499.s15|56-65|volunteers|O
DDI-DrugBank.d499.s15|66-66|,|O
DDI-DrugBank.d499.s15|68-77|ketoprofen|drug
DDI-DrugBank.d499.s15|79-81|did|O
DDI-DrugBank.d499.s15|83-85|not|O
DDI-DrugBank.d499.s15|87-99|significantly|O
DDI-DrugBank.d499.s15|101-109|interfere|O
DDI-DrugBank.d499.s15|111-114|with|O
DDI-DrugBank.d499.s15|116-118|the|O
DDI-DrugBank.d499.s15|120-125|effect|O
DDI-DrugBank.d499.s15|127-128|of|O
DDI-DrugBank.d499.s15|130-137|warfarin|drug
DDI-DrugBank.d499.s15|139-140|on|O
DDI-DrugBank.d499.s15|142-152|prothrombin|O
DDI-DrugBank.d499.s15|154-157|time|O
DDI-DrugBank.d499.s15|158-158|.|O
DDI-DrugBank.d499.s16|0-7|Bleeding|O
DDI-DrugBank.d499.s16|9-12|from|O
DDI-DrugBank.d499.s16|14-14|a|O
DDI-DrugBank.d499.s16|16-21|number|O
DDI-DrugBank.d499.s16|23-24|of|O
DDI-DrugBank.d499.s16|26-30|sites|O
DDI-DrugBank.d499.s16|32-34|may|O
DDI-DrugBank.d499.s16|36-37|be|O
DDI-DrugBank.d499.s16|39-39|a|O
DDI-DrugBank.d499.s16|41-52|complication|O
DDI-DrugBank.d499.s16|54-55|of|O
DDI-DrugBank.d499.s16|57-64|warfarin|drug
DDI-DrugBank.d499.s16|66-74|treatment|O
DDI-DrugBank.d499.s16|76-78|and|O
DDI-DrugBank.d499.s16|80-81|GI|O
DDI-DrugBank.d499.s16|83-90|bleeding|O
DDI-DrugBank.d499.s16|92-92|a|O
DDI-DrugBank.d499.s16|94-105|complication|O
DDI-DrugBank.d499.s16|107-108|of|O
DDI-DrugBank.d499.s16|110-119|ketoprofen|drug
DDI-DrugBank.d499.s16|121-129|treatment|O
DDI-DrugBank.d499.s16|130-130|.|O
DDI-DrugBank.d499.s17|0-6|Because|O
DDI-DrugBank.d499.s17|8-21|prostaglandina|O
DDI-DrugBank.d499.s17|23-26|play|O
DDI-DrugBank.d499.s17|28-29|an|O
DDI-DrugBank.d499.s17|31-39|important|O
DDI-DrugBank.d499.s17|41-44|role|O
DDI-DrugBank.d499.s17|46-47|in|O
DDI-DrugBank.d499.s17|49-58|hemostasis|O
DDI-DrugBank.d499.s17|60-62|and|O
DDI-DrugBank.d499.s17|64-73|ketoprofen|drug
DDI-DrugBank.d499.s17|75-77|has|O
DDI-DrugBank.d499.s17|79-80|an|O
DDI-DrugBank.d499.s17|82-87|effect|O
DDI-DrugBank.d499.s17|89-90|on|O
DDI-DrugBank.d499.s17|92-99|platelet|O
DDI-DrugBank.d499.s17|101-108|function|O
DDI-DrugBank.d499.s17|110-111|as|O
DDI-DrugBank.d499.s17|113-116|well|O
DDI-DrugBank.d499.s17|117-117|,|O
DDI-DrugBank.d499.s17|119-127|concurent|O
DDI-DrugBank.d499.s17|129-135|therapy|O
DDI-DrugBank.d499.s17|137-140|with|O
DDI-DrugBank.d499.s17|142-151|ketoprofen|drug
DDI-DrugBank.d499.s17|153-155|and|O
DDI-DrugBank.d499.s17|157-164|warfarin|drug
DDI-DrugBank.d499.s17|166-173|requires|O
DDI-DrugBank.d499.s17|175-179|close|O
DDI-DrugBank.d499.s17|181-190|monitoring|O
DDI-DrugBank.d499.s17|192-193|of|O
DDI-DrugBank.d499.s17|195-202|patients|O
DDI-DrugBank.d499.s17|204-205|on|O
DDI-DrugBank.d499.s17|207-210|both|O
DDI-DrugBank.d499.s17|212-216|drugs|O
DDI-DrugBank.d499.s17|217-217|.|O
DDI-DrugBank.d499.s18|0-0|6|O
DDI-DrugBank.d499.s18|1-1|.|O
DDI-DrugBank.d499.s19|0-9|Probenecid|drug
DDI-DrugBank.d499.s19|10-10|:|O
DDI-DrugBank.d499.s19|12-21|Probenecid|drug
DDI-DrugBank.d499.s19|23-31|increases|O
DDI-DrugBank.d499.s19|33-36|both|O
DDI-DrugBank.d499.s19|38-41|free|O
DDI-DrugBank.d499.s19|43-45|and|O
DDI-DrugBank.d499.s19|47-51|bound|O
DDI-DrugBank.d499.s19|53-62|ketoprofen|O
DDI-DrugBank.d499.s19|64-65|by|O
DDI-DrugBank.d499.s19|67-74|reducing|O
DDI-DrugBank.d499.s19|76-78|the|O
DDI-DrugBank.d499.s19|80-85|plasma|O
DDI-DrugBank.d499.s19|87-95|clearance|O
DDI-DrugBank.d499.s19|97-98|of|O
DDI-DrugBank.d499.s19|100-109|ketoprofen|drug
DDI-DrugBank.d499.s19|111-112|to|O
DDI-DrugBank.d499.s19|114-118|about|O
DDI-DrugBank.d499.s19|120-128|one-third|O
DDI-DrugBank.d499.s19|129-129|,|O
DDI-DrugBank.d499.s19|131-132|as|O
DDI-DrugBank.d499.s19|134-137|well|O
DDI-DrugBank.d499.s19|139-140|as|O
DDI-DrugBank.d499.s19|142-151|decreasing|O
DDI-DrugBank.d499.s19|153-155|its|O
DDI-DrugBank.d499.s19|157-163|protein|O
DDI-DrugBank.d499.s19|165-171|binding|O
DDI-DrugBank.d499.s19|172-172|.|O
DDI-DrugBank.d499.s20|0-8|Therefore|O
DDI-DrugBank.d499.s20|9-9|,|O
DDI-DrugBank.d499.s20|11-13|the|O
DDI-DrugBank.d499.s20|15-25|combination|O
DDI-DrugBank.d499.s20|27-28|of|O
DDI-DrugBank.d499.s20|30-39|ketoprofen|drug
DDI-DrugBank.d499.s20|41-43|and|O
DDI-DrugBank.d499.s20|45-54|probenecid|drug
DDI-DrugBank.d499.s20|56-57|is|O
DDI-DrugBank.d499.s20|59-61|not|O
DDI-DrugBank.d499.s20|63-73|recommended|O
DDI-DrugBank.d499.s20|74-74|.|O
DDI-DrugBank.d499.s21|0-0|7|O
DDI-DrugBank.d499.s21|1-1|.|O
DDI-DrugBank.d499.s22|0-11|Methotrexate|drug
DDI-DrugBank.d499.s22|12-12|:|O
DDI-DrugBank.d499.s22|14-23|Ketoprofen|drug
DDI-DrugBank.d499.s22|24-24|,|O
DDI-DrugBank.d499.s22|26-29|like|O
DDI-DrugBank.d499.s22|31-35|other|O
DDI-DrugBank.d499.s22|37-42|NSAIDs|group
DDI-DrugBank.d499.s22|43-43|,|O
DDI-DrugBank.d499.s22|45-47|may|O
DDI-DrugBank.d499.s22|49-53|cause|O
DDI-DrugBank.d499.s22|55-61|changes|O
DDI-DrugBank.d499.s22|63-64|in|O
DDI-DrugBank.d499.s22|66-68|the|O
DDI-DrugBank.d499.s22|70-80|elimination|O
DDI-DrugBank.d499.s22|82-83|of|O
DDI-DrugBank.d499.s22|85-96|methotrexate|drug
DDI-DrugBank.d499.s22|98-104|leading|O
DDI-DrugBank.d499.s22|106-107|to|O
DDI-DrugBank.d499.s22|109-116|elevated|O
DDI-DrugBank.d499.s22|118-122|serum|O
DDI-DrugBank.d499.s22|124-129|levels|O
DDI-DrugBank.d499.s22|131-132|of|O
DDI-DrugBank.d499.s22|134-136|the|O
DDI-DrugBank.d499.s22|138-141|drug|O
DDI-DrugBank.d499.s22|143-145|and|O
DDI-DrugBank.d499.s22|147-155|increased|O
DDI-DrugBank.d499.s22|157-164|toxicity|O
DDI-DrugBank.d499.s22|165-165|.|O
DDI-DrugBank.d499.s23|0-0|8|O
DDI-DrugBank.d499.s23|1-1|.|O
DDI-DrugBank.d499.s24|0-6|Lithium|drug
DDI-DrugBank.d499.s24|7-7|:|O
DDI-DrugBank.d499.s24|9-45|Nonsteroidal anti-inflammatory agents|group
DDI-DrugBank.d499.s24|47-50|have|O
DDI-DrugBank.d499.s24|52-55|been|O
DDI-DrugBank.d499.s24|57-64|reported|O
DDI-DrugBank.d499.s24|66-67|to|O
DDI-DrugBank.d499.s24|69-76|increase|O
DDI-DrugBank.d499.s24|78-88|steadystate|O
DDI-DrugBank.d499.s24|90-95|plasma|O
DDI-DrugBank.d499.s24|97-103|lithium|drug
DDI-DrugBank.d499.s24|105-110|levels|O
DDI-DrugBank.d499.s24|111-111|.|O
DDI-DrugBank.d499.s25|0-1|It|O
DDI-DrugBank.d499.s25|3-4|is|O
DDI-DrugBank.d499.s25|6-16|recommended|O
DDI-DrugBank.d499.s25|18-21|that|O
DDI-DrugBank.d499.s25|23-28|plasma|O
DDI-DrugBank.d499.s25|30-36|lithium|drug
DDI-DrugBank.d499.s25|38-43|levels|O
DDI-DrugBank.d499.s25|45-46|be|O
DDI-DrugBank.d499.s25|48-56|monitored|O
DDI-DrugBank.d499.s25|58-61|when|O
DDI-DrugBank.d499.s25|63-72|ketoprofen|drug
DDI-DrugBank.d499.s25|74-75|is|O
DDI-DrugBank.d499.s25|77-90|coadministered|O
DDI-DrugBank.d499.s25|92-95|with|O
DDI-DrugBank.d499.s25|97-103|lithium|drug
DDI-DrugBank.d499.s25|104-104|.|O
DDI-DrugBank.d499.s26|0-14|DRUG/LABORATORY|O
DDI-DrugBank.d499.s26|16-19|TEST|O
DDI-DrugBank.d499.s26|21-32|INTERACTIONS|O
DDI-DrugBank.d499.s26|33-33|:|O
DDI-DrugBank.d499.s26|35-40|EFFECT|O
DDI-DrugBank.d499.s26|42-43|ON|O
DDI-DrugBank.d499.s26|45-49|BLOOD|O
DDI-DrugBank.d499.s26|51-61|COAGULATION|O
DDI-DrugBank.d499.s26|63-72|Ketoprofen|drug
DDI-DrugBank.d499.s26|74-82|decreases|O
DDI-DrugBank.d499.s26|84-91|platelet|O
DDI-DrugBank.d499.s26|93-100|adhesion|O
DDI-DrugBank.d499.s26|102-104|and|O
DDI-DrugBank.d499.s26|106-116|aggregation|O
DDI-DrugBank.d499.s26|117-117|.|O
DDI-DrugBank.d499.s27|0-8|Therefore|O
DDI-DrugBank.d499.s27|9-9|,|O
DDI-DrugBank.d499.s27|11-12|it|O
DDI-DrugBank.d499.s27|14-16|can|O
DDI-DrugBank.d499.s27|18-24|prolong|O
DDI-DrugBank.d499.s27|26-33|bleeding|O
DDI-DrugBank.d499.s27|35-38|time|O
DDI-DrugBank.d499.s27|40-41|by|O
DDI-DrugBank.d499.s27|43-55|approximately|O
DDI-DrugBank.d499.s27|57-57|3|O
DDI-DrugBank.d499.s27|59-60|to|O
DDI-DrugBank.d499.s27|62-62|4|O
DDI-DrugBank.d499.s27|64-70|minutes|O
DDI-DrugBank.d499.s27|72-75|from|O
DDI-DrugBank.d499.s27|77-84|baseline|O
DDI-DrugBank.d499.s27|86-91|values|O
DDI-DrugBank.d499.s27|92-92|.|O
DDI-DrugBank.d499.s28|0-4|There|O
DDI-DrugBank.d499.s28|6-7|is|O
DDI-DrugBank.d499.s28|9-10|no|O
DDI-DrugBank.d499.s28|12-22|significant|O
DDI-DrugBank.d499.s28|24-29|change|O
DDI-DrugBank.d499.s28|31-32|in|O
DDI-DrugBank.d499.s28|34-41|platelet|O
DDI-DrugBank.d499.s28|43-47|count|O
DDI-DrugBank.d499.s28|48-48|,|O
DDI-DrugBank.d499.s28|50-60|prothrombin|O
DDI-DrugBank.d499.s28|62-65|time|O
DDI-DrugBank.d499.s28|66-66|,|O
DDI-DrugBank.d499.s28|68-74|partial|O
DDI-DrugBank.d499.s28|76-89|thromboplastin|O
DDI-DrugBank.d499.s28|91-94|time|O
DDI-DrugBank.d499.s28|95-95|,|O
DDI-DrugBank.d499.s28|97-98|or|O
DDI-DrugBank.d499.s28|100-107|thrombin|O
DDI-DrugBank.d499.s28|109-112|time|O
DDI-DrugBank.d499.s28|113-113|.|O
DDI-MedLine.d111.s0|0-5|Effect|O
DDI-MedLine.d111.s0|7-8|of|O
DDI-MedLine.d111.s0|10-23|coadministered|O
DDI-MedLine.d111.s0|25-29|drugs|O
DDI-MedLine.d111.s0|31-33|and|O
DDI-MedLine.d111.s0|35-41|ethanol|drug
DDI-MedLine.d111.s0|43-44|on|O
DDI-MedLine.d111.s0|46-48|the|O
DDI-MedLine.d111.s0|50-56|binding|O
DDI-MedLine.d111.s0|58-59|of|O
DDI-MedLine.d111.s0|61-71|therapeutic|O
DDI-MedLine.d111.s0|73-77|drugs|O
DDI-MedLine.d111.s0|79-80|to|O
DDI-MedLine.d111.s0|82-86|human|O
DDI-MedLine.d111.s0|88-92|serum|O
DDI-MedLine.d111.s0|94-95|in|O
DDI-MedLine.d111.s0|97-101|vitro|O
DDI-MedLine.d111.s0|102-102|.|O
DDI-MedLine.d111.s1|0-2|The|O
DDI-MedLine.d111.s1|4-10|effects|O
DDI-MedLine.d111.s1|12-13|of|O
DDI-MedLine.d111.s1|15-28|coadministered|O
DDI-MedLine.d111.s1|30-34|drugs|O
DDI-MedLine.d111.s1|36-38|and|O
DDI-MedLine.d111.s1|40-46|ethanol|drug
DDI-MedLine.d111.s1|48-49|on|O
DDI-MedLine.d111.s1|51-53|the|O
DDI-MedLine.d111.s1|55-61|binding|O
DDI-MedLine.d111.s1|63-64|of|O
DDI-MedLine.d111.s1|66-76|therapeutic|O
DDI-MedLine.d111.s1|78-82|drugs|O
DDI-MedLine.d111.s1|84-85|to|O
DDI-MedLine.d111.s1|87-91|human|O
DDI-MedLine.d111.s1|93-97|serum|O
DDI-MedLine.d111.s1|99-100|in|O
DDI-MedLine.d111.s1|102-106|vitro|O
DDI-MedLine.d111.s1|108-110|was|O
DDI-MedLine.d111.s1|112-123|investigated|O
DDI-MedLine.d111.s1|124-124|.|O
DDI-MedLine.d111.s2|0-12|Acetaminophen|drug
DDI-MedLine.d111.s2|13-13|,|O
DDI-MedLine.d111.s2|15-23|lidocaine|drug
DDI-MedLine.d111.s2|24-24|,|O
DDI-MedLine.d111.s2|26-38|phenobarbital|drug
DDI-MedLine.d111.s2|39-39|,|O
DDI-MedLine.d111.s2|41-49|quinidine|drug
DDI-MedLine.d111.s2|50-50|,|O
DDI-MedLine.d111.s2|52-63|theophylline|drug
DDI-MedLine.d111.s2|64-64|,|O
DDI-MedLine.d111.s2|66-68|and|O
DDI-MedLine.d111.s2|70-82|valproic acid|drug
DDI-MedLine.d111.s2|84-87|were|O
DDI-MedLine.d111.s2|89-93|added|O
DDI-MedLine.d111.s2|95-96|to|O
DDI-MedLine.d111.s2|98-103|pooled|O
DDI-MedLine.d111.s2|105-109|human|O
DDI-MedLine.d111.s2|111-115|serum|O
DDI-MedLine.d111.s2|117-118|at|O
DDI-MedLine.d111.s2|120-130|therapeutic|O
DDI-MedLine.d111.s2|132-145|concentrations|O
DDI-MedLine.d111.s2|146-146|.|O
DDI-MedLine.d111.s3|0-1|To|O
DDI-MedLine.d111.s3|3-6|each|O
DDI-MedLine.d111.s3|8-18|preparation|O
DDI-MedLine.d111.s3|20-22|was|O
DDI-MedLine.d111.s3|24-28|added|O
DDI-MedLine.d111.s3|30-32|one|O
DDI-MedLine.d111.s3|34-43|additional|O
DDI-MedLine.d111.s3|45-48|drug|O
DDI-MedLine.d111.s3|50-51|at|O
DDI-MedLine.d111.s3|53-57|three|O
DDI-MedLine.d111.s3|59-72|concentrations|O
DDI-MedLine.d111.s3|74-80|ranging|O
DDI-MedLine.d111.s3|82-85|from|O
DDI-MedLine.d111.s3|87-97|therapeutic|O
DDI-MedLine.d111.s3|99-100|to|O
DDI-MedLine.d111.s3|102-106|toxic|O
DDI-MedLine.d111.s3|107-107|.|O
DDI-MedLine.d111.s4|0-2|The|O
DDI-MedLine.d111.s4|4-12|following|O
DDI-MedLine.d111.s4|14-18|eight|O
DDI-MedLine.d111.s4|20-25|target|O
DDI-MedLine.d111.s4|27-36|drug/added|O
DDI-MedLine.d111.s4|38-41|drug|O
DDI-MedLine.d111.s4|43-54|combinations|O
DDI-MedLine.d111.s4|56-59|were|O
DDI-MedLine.d111.s4|61-67|studied|O
DDI-MedLine.d111.s4|68-68|:|O
DDI-MedLine.d111.s4|70-96|acetaminophen/phenobarbital|drug
DDI-MedLine.d111.s4|97-97|.|O
DDI-MedLine.d111.s5|0-25|acetaminophen/theophylline|drug
DDI-MedLine.d111.s5|26-26|,|O
DDI-MedLine.d111.s5|28-46|lidocaine/quinidine|drug
DDI-MedLine.d111.s5|47-47|,|O
DDI-MedLine.d111.s5|49-75|phenobarbital/acetaminophen|drug
DDI-MedLine.d111.s5|76-76|,|O
DDI-MedLine.d111.s5|78-104|phenobarbital/valproic acid|drug
DDI-MedLine.d111.s5|105-105|,|O
DDI-MedLine.d111.s5|107-125|quinidine/lidocaine|drug
DDI-MedLine.d111.s5|126-126|,|O
DDI-MedLine.d111.s5|128-153|theophylline/acetaminophen|drug
DDI-MedLine.d111.s5|154-154|,|O
DDI-MedLine.d111.s5|156-158|and|O
DDI-MedLine.d111.s5|160-167|valproic|O
DDI-MedLine.d111.s5|169-186|acid/phenobarbital|drug
DDI-MedLine.d111.s5|187-187|.|O
DDI-MedLine.d111.s6|0-3|Each|O
DDI-MedLine.d111.s6|5-9|serum|O
DDI-MedLine.d111.s6|11-17|without|O
DDI-MedLine.d111.s6|19-21|the|O
DDI-MedLine.d111.s6|23-27|other|O
DDI-MedLine.d111.s6|29-33|added|O
DDI-MedLine.d111.s6|35-38|drug|O
DDI-MedLine.d111.s6|40-41|as|O
DDI-MedLine.d111.s6|43-46|well|O
DDI-MedLine.d111.s6|48-49|as|O
DDI-MedLine.d111.s6|51-53|the|O
DDI-MedLine.d111.s6|55-59|serum|O
DDI-MedLine.d111.s6|61-72|supplemented|O
DDI-MedLine.d111.s6|74-77|with|O
DDI-MedLine.d111.s6|79-81|the|O
DDI-MedLine.d111.s6|83-87|other|O
DDI-MedLine.d111.s6|89-92|drug|O
DDI-MedLine.d111.s6|94-95|at|O
DDI-MedLine.d111.s6|97-99|the|O
DDI-MedLine.d111.s6|101-105|three|O
DDI-MedLine.d111.s6|107-120|concentrations|O
DDI-MedLine.d111.s6|122-124|was|O
DDI-MedLine.d111.s6|126-133|dialyzed|O
DDI-MedLine.d111.s6|135-141|against|O
DDI-MedLine.d111.s6|143-151|phosphate|O
DDI-MedLine.d111.s6|153-158|buffer|O
DDI-MedLine.d111.s6|159-159|.|O
DDI-MedLine.d111.s7|0-8|Similarly|O
DDI-MedLine.d111.s7|10-17|dialyzed|O
DDI-MedLine.d111.s7|19-22|were|O
DDI-MedLine.d111.s7|24-36|phenobarbital|drug
DDI-MedLine.d111.s7|37-37|,|O
DDI-MedLine.d111.s7|39-47|quinidine|drug
DDI-MedLine.d111.s7|48-48|,|O
DDI-MedLine.d111.s7|50-52|and|O
DDI-MedLine.d111.s7|54-65|theophylline|drug
DDI-MedLine.d111.s7|66-66|,|O
DDI-MedLine.d111.s7|68-71|both|O
DDI-MedLine.d111.s7|73-77|alone|O
DDI-MedLine.d111.s7|79-80|at|O
DDI-MedLine.d111.s7|82-92|therapeutic|O
DDI-MedLine.d111.s7|94-107|concentrations|O
DDI-MedLine.d111.s7|109-110|in|O
DDI-MedLine.d111.s7|112-116|serum|O
DDI-MedLine.d111.s7|118-120|and|O
DDI-MedLine.d111.s7|122-125|with|O
DDI-MedLine.d111.s7|127-133|ethanol|drug
DDI-MedLine.d111.s7|135-136|at|O
DDI-MedLine.d111.s7|138-142|three|O
DDI-MedLine.d111.s7|144-152|different|O
DDI-MedLine.d111.s7|154-167|concentrations|O
DDI-MedLine.d111.s7|169-170|in|O
DDI-MedLine.d111.s7|172-176|serum|O
DDI-MedLine.d111.s7|177-177|.|O
DDI-MedLine.d111.s8|0-2|The|O
DDI-MedLine.d111.s8|4-13|percentage|O
DDI-MedLine.d111.s8|15-16|of|O
DDI-MedLine.d111.s8|18-21|drug|O
DDI-MedLine.d111.s8|23-29|binding|O
DDI-MedLine.d111.s8|31-32|in|O
DDI-MedLine.d111.s8|34-37|each|O
DDI-MedLine.d111.s8|39-49|preparation|O
DDI-MedLine.d111.s8|51-53|was|O
DDI-MedLine.d111.s8|55-64|calculated|O
DDI-MedLine.d111.s8|65-65|.|O
